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ABSTRACT 
 
Aortic Valve Bypass surgery has found renewed interest to researchers due to its 
application in high-risk patients with severe aortic stenosis. This therapy consists of 
construction of a conduit containing a bioprosthetic or mechanical valve from the apex of 
the left ventricle to the descending thoracic aorta. Blood is ejected from the left ventricle 
via both the native stenotic aortic valve and the conduit. This thesis proposes a design for 
one of the least developed components of this system, the cannula component that sits 
inside the left ventricle and allows for flow of blood from the left ventricle and into the 
conduit. Experimental use of mock flow loop testing and computational flow dynamics 
analysis (ANSYS Inc., Canonsburg, PA, U.S.A.) on prototype and currently used clinical 
venous cannulas were used in the development and design of the proposed apical 
cannula. Aortic valve bypass results in a low gradient across the native stenotic valve and 
a small gradient across the conduit. The results from the mock loop experiments, CFD 
analysis, clinical data, and findings from previous researchers have aided in design of a 
new apical cannula. It is hoped that this cannula will be a more favorable design over 
currently used apical connectors. Further in vitro and in vivo studies are needed to 
validate these results. 
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I. INTRODUCTION  
Treatment of aortic stenosis through surgical replacement has been one of the 
most successful advances in cardiovascular medicine and has increased the quality of life 
for patients worldwide (1). However, use of this technique in certain patient populations, 
specifically the elderly, has been associated with increased mortality rates (2). A growing 
alternative therapy for these populations is implantation of Aortic Valve Bypass (AVB) 
(3). In simplest terms, this alternative creates a second path for blood ejected from the left 
heart by creating a one-way conduit between the apex of the left ventricle and the 
descending aorta. The overall resistance of the blood being pumped to the rest of the 
body is thereby decreased by the creation of two paths to follow.  
The AVB system consists of three main components: a bioprosthetic or 
mechanical valve, an apical cannula inserted into the left ventricular apex, and bypass 
conduit material connecting these components. Blood is ejected from the left ventricle via 
both the native stenotic aortic valve and the AVB conduit. The advantages of AVB lie in 
the decreased surgical risks as compared to conventional aortic valve replacement (AVR) 
in high-risk patient population pools.  AVR requires cardiopulmonary bypass, ascending 
aortic crossclamping, aortotomy, debridement of the diseased valve, and cardioplegic 
cardiac arrest which are all avoided in the AVB surgical approach.  
The focus of this report is on the design and testing of a critical component in the 
AVB system, the apical cannula inserted into the apex of the left ventricle. There has 
been much research devoted in the past into the development of the valve and conduit 
design (2,4,5). Design and testing of artificial heart valves for surgical replacement have 
been refined over the course of over 4 decades while research on conduit materials have 
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increased with the advent of Ventricle Assist Devices (VAD). Though, currently there is 
little research on the optimization of the apical cannula at the insertion point of the 
conduit.  
Important factors in creation of the cannula include the tip design, inlet diameter 
size, number of sideholes, and flow profile. The novel aspects of the proposed design are 
in the use of Pyrolitic Carbon (PYC) for fabrication and the modified Seldinger surgical 
implantation technique used (6,7). PYC has been used for decades in prosthetic valves 
and shows significant biocompatibility in the body. The modified Seldinger technique 
provides a simple and quick insertion procedure designed to decrease operating time and 
improve patient outcomes. 
A series of experiments was completed to shape the design and characteristics of 
the prototypes. This includes use of mock flow loop testing and Computational Flow 
Dynamics (ANSYS Inc., Canonsburg, PA, U.S.A.). Mock loop testing was performed at 
the Cardiovascular Innovation Institute in Louisville, KY. The cannula was produced 
with the use of CAD modeling (SolidWorks SP3.0, Dassault Systèmes; Vélizy, France) 
and employed the use of a proprietary manufacturing process for fabrication (ATS 
Medical; Minneapolis, MN). This report presents a design of an apical cannula for use in 
aortic valve bypass. Further experimentation and animal studies will be needed in future 
development of this promising technology. 
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II. OBJECTIVES 
 The main objective of this work is the design of a new apical cannula to be used 
in the AVB system. This was accomplished by testing of a series of clinically available 
cardiopulmonary bypass venous cannulas, a prototype cannula, and CFD analysis of 
computer generated cannula models. The end result of this testing is a new proposed 
apical cannula presented in Section X. 
 Section III provides a background into aortic valve bypass and details the benefits 
of AVB over AVR in high risk patient populations. Section IV details the design process 
followed in the development of the cannula, as well as the novel aspects, properties, and 
techniques associated with the cannula. This section also presents the preliminary 
prototype, a cannula produced for testing. 
 Sections V, VI, and VII describe the methods, instrumentation, and the results, 
respectively, of experiments performed on the cannulas. These testing methods included 
three flow loop experiments and CFD analysis. Section VIII discusses the results of the 
experiments and provides insight into the properties of the cannula. Section IX wraps up 
the work with conclusions and ideas for future work. The final section, based from the 
conclusions of the experiments, presents a final design for an apical cannula proposed 
Section X.  
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III. BACKGROUND 
The aortic valve is a semilunar, tricuspid valve positioned between the aorta and 
left ventricle at the end of the left ventricular outflow tract. The normal working of this 
valve is critical to maintaining efficient cardiac function. During ventricular systole, 
pressure rises in the left ventricle. When the pressure in the left ventricle rises above the 
pressure in the aorta, the aortic valve opens, allowing blood to exit the left ventricle into 
the aorta. When ventricular systole ends, pressure in the left ventricle rapidly drops and 
the aortic pressure forces the aortic valve to close.  
The opening and closing of the aortic valve is a passive mechanism responding to 
the pressure fluctuations of the cardiac cycle, particularly the pressure differences 
between the left ventricular chamber and the aorta. Although pressure changes during the 
cardiac cycle may create some structural changes in the valve mechanism to facilitate 
opening or closing, the principal component of valvular function is the pressure 
difference between the left ventricle and the aorta. (8) 
 
Aortic Stenosis 
Aortic Stenosis (AS) is the narrowing of the native valve controlling blood flow 
between the left ventricle and aorta in the heart. As the valve narrows, it impedes the flow 
of blood to the rest of the body and can lead to a host of physiologic complications, 
including congestive heart failure. When the aortic valve becomes stenotic, it causes an 
increase in the pressure gradient between the left ventricle (LV) and the aorta during 
systole. The more constricted the valve, the higher the pressure gradient between the LV 
and the aorta. Figure 1 shows the differences between normal and stenotic valves. 
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FIGURE 1 - Location of Aortic valve in the heart which controls the flow of blood from 
the left ventricle to the Aorta (left). Transverse view of a normal aortic valve seen from 
the top (center). Similar view of a stenotic aortic valve (right). 
 
AS is the most common of valvular defects and develops mainly in the elderly 
population (9). It is primarily caused by three conditions: congenital defects, 
calcification, or scarring caused by disease.  
The most common source of AS of the three main causes is degenerative 
calcification of the aortic valve. This is a condition where large calcium deposits form on 
the aortic valve leaflets. Over time the leaflets will harden and thicken, a condition called 
aortic sclerosis, which will develop into AS.  Although previously considered to be the 
result of years of mechanical stress on an otherwise normal valve, it is now believed that 
the degenerative process leads to inflammatory changes, with lipid accumulation, 
upregulation of angiotensin converting enzyme (ACE) activity, and infiltration of 
macrophages and T lymphocytes ultimately leading to calcification of the aortic valve 
(10). 
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Congenitally, many patients are born with a bicuspid or a unicommissural aortic 
valve, an anatomic variant which the aortic valve consists of one or two leaflets that 
frequently evolves into stenosis. Bicuspid aortic valves are present in approximately 2% 
of the general population (10). Gradual calcification of the bicuspid aortic valve results in 
significant stenosis most often with patients in their late 50’s or 60’s. This becomes more 
prevalent earlier in unicommissural than in bicuspid valves and earlier in men than in 
women. The underlying causing the development of AS in these patients is due to the 
abnormal architecture of the unicommissural or bicuspid aortic valve which induces 
turbulent flow. Turbulent flow injures the leaflets and leads to fibrosis, increased rigidity, 
leaflet calcification, and narrowing of the aortic valve orifice. 
The last main cause in the development of AS is scarring of the heart’s aortic 
valve which is caused by a number of factors. A large number of AS cases in the past 
arose from scarring induced from rheumatic fever. Rheumatic AS currently represents the 
least common form of AS in the adult population and usually occurs in conjunction with 
mitral valve stenosis (1). Rheumatic AS is characterized by diffuse fibrous leaflet 
thickening of the valve with fusion to a variable extent of one or two commissures. 
Overall distribution of causes of AS varies significantly among different age 
groups. Among patients younger than 70 years of age, congenitally calcified bicuspid 
valves were responsible for half of surgical cases. Though, in patients over 70 years of 
age, degenerative calcific stenosis is the most prevalent cause of stenosis. The prevalence 
of AS is growing rapidly within the aging population of the United States. Nkomo et al. 
completed a population based study with over 12,000 randomly selected adults from the 
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general population (11). They noted that moderate or severe valvular diseases are 
common and increase with age as seen in Figure 2.  
 
FIGURE 2 - Prevalence of valvular disease in general population based on age. Note the 
steep increase in prevalence rate in those 65 years of age and older. 
  
Classification Criteria for Aortic Stenosis 
Surveillance of the aortic valve for calcification and deterioration of the AS 
monitored by jet velocity, measurement of aortic valve area, and transvalvular pressure 
gradient are important clinical factors in identifying populations of AS patients at risk. 
The severity of AS is assessed by estimating the mean systolic gradient and aortic valve 
area (AVA). In 2006, the American College of Cardiology/American Heart Association 
Task Force on Practice Guidelines (ACC/AHA Practice Guidelines) published a report 
outlining the definition and care for valvular diseases (12). A classification of severity 
that incorporates 3 measurable factors in AS was proposed. Estimation of aortic valvular 
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area and maximum aortic velocity of the blood column during systole, as well as peak 
and mean pressure gradients across the stenotic valve can be achieved using Doppler 
echocardiography and pressure catheter measurement. 
In these guidelines, AS is graded as mild for AVA greater than 1.5 cm2, moderate 
for areas between 1.0 and 1.5 cm2, and severe for a valve area less than 1.0 cm2. The 
criteria for mild, moderate, and severe AS, when analyzing measured jet velocity in 
meters per second, are less than 3.0, 3.0 to 4.0, and greater than 4.0, respectively. The 
transvalvular pressure gradient is best measured with a catheter in the left ventricle and 
another in the proximal aorta.  
The peak-to-peak gradient is measured as the difference between peak left 
ventricular pressure and peak aortic pressure and commonly used to quantify the valve 
gradient. A mean gradient across the aortic valve of less than 25 mm Hg is classified as 
mild AS, severe AS is defined by a mean pressure drop greater than 40 mm Hg, and 
moderate AS lies between mild and severe. Most patients with AS have surgery when the 
AVA is less than 0.7 cm2 or there is a mean systolic gradient of more than 50 mm Hg, 
though patients may become symptomatic sooner and require AVR before these 
thresholds are reached (9). 
 
Current Treatments for AS 
To date, there is no conclusive evidence to support optimal medical management 
of AS and in the past have shown dismal prognosis for patients (9). Rosenhek and 
colleagues identified 128 consecutive patients with severe AS with an aortic jet velocity 
of 5.0 +/- 0.6 m/s and followed them prospectively for 22 +/- 18 months (13).  An event 
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was defined as either death (8 patients) or surgical replacement (AVR). At one year two-
thirds of the patients remained event free, and by four years only a third remained event 
free. Of those patients whose aortic jet velocity increased by more than 0.3 meters per 
second per year, 80% died or underwent AVR within 2 years. The severity of aortic valve 
calcification was an independent predictor of event-free survival. Absence of or minimal 
valvular calcification predicted a 75% event-free survival at 4 years. Only 20% of those 
with moderate to severe calcification remained event free at 4 years (13). 
A larger study of 622 patients with severe, asymptomatic AS as defined by a peak 
jet velocity of greater than 4 m/s were completed by Pellikka and colleagues (14). At 5-
year follow-up only 25% of the patients remained free of surgery or cardiac death and 
only one-third remained symptom free. One-third of patients developed cardiac 
symptoms of angina, syncope, or dyspnea before surgery within 2 years. They identified 
a statistical risk of sudden death of approximately 1% per year in un-operated patients 
(14). In large part due to data published, the ACC/AHA Practice Guidelines (12) have 
said, ‘‘there are no medical treatments proven to prevent or delay the disease process in 
the aortic valve leaflets.’’ It seems the best treatment option for patients with severe AS is 
a surgical intervention, which most commonly is through aortic valve replacement 
(AVR). 
Alternative therapies include new developments in percutaneous deployment of 
aortic valves in stents (percutaneous aortic valve replacement, PAVR) and a revival of a 
surgical treatment known as an aortic valve bypass (AVB). There are two approaches to 
PAVR, an antegrade and retrograde approach, which have seen some success in high risk 
patient groups (9). PAVR is still in its experimental stages and carries significant risks, 
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though its potential as an alternate therapy is very promising. The techniques proposed in 
this thesis work advocate the use of aortic valve bypass for treatment in high risk patients. 
 
Aortic Valve Replacement 
The current and most routinely used treatment for severe AS is aortic valve 
replacement (AVR). Since its first use in 1961, the basic procedure has remained 
unchanged and over 180,000 procedures are now performed annually worldwide (15). 
The procedure for AVR surgically removes the patient’s stenotic aortic valve and 
replaces it with either a bioprosthetic valve or a mechanical valve.  AVR commonly 
demands the use of cardiopulmonary bypass, ascending aortic crossclamping, aortotomy, 
debridement of the diseased valve, and cardioplegic cardiac arrest; it therefore carries a 
finite risk of morbidity and mortality. 
Outcomes after conventional AVR, although clearly superior to untreated AS, 
remain imperfect. Table I shows recent data from the 2008 Society of Thoracic Surgeons 
(STS) database. Operative mortality remains fairly low at 4%, but increases with high 
risk patient groups. Although operative mortality is an important outcome for any 
therapeutic intervention for aortic stenosis, it is also important to consider the morbidity 
associated with cardiac surgery.  
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TABLE I 
STATISTICS FOR AVR, SOURCE: STS DATABASE 2008. 
 
In the 2001 STS report, the risk for stroke was 1.58%, renal failure 3.70%, and 
reoperation for bleeding 4.12% (2). Figure 3 shows that survival rates decrease with age 
(16). One report shows that for patients 80 years of age and older undergoing AVR, the 
immediate mortality is 10% (17). The risks of operative conditions increase the morality 
rates in the high-risk elderly population, though this treatment is comparatively better 
than no intervention. 
 
 
FIGURE 3 - Long term survival rates for AVR for over 13,000 patients as published by 
Blackstone et al. 
AVR Statistics Mean
Age 66 Years
Reoperation 17%
Cross-clamp time 80 min
Perfusion time 110 min
Operative Mortality 4%
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Despite the mortality, the number of patients older than 80 years undergoing AVR 
is significant. As the population ages, and without an alternative therapeutic option, 
surgery in these high-risk patients continues (9). For patients with severe AS who refuse 
surgery, the average survival is 2 years or less (18). Of the octogenarians surviving the 
initial postoperative period of 60 days, two-thirds survived 3 years or longer, and 40% 
were alive 5 or more years after surgery (17). Because symptomatic AS is an indication 
for surgery, alleviation of symptoms postoperatively is a factor in assessing surgical risk 
and benefit. In the elderly, relief of symptoms may be of even greater importance than 
long-term survival data. Patients and physicians alike are therefore willing to undertake 
AVR even in light of significant immediate mortality (9). 
 
Aortic Valve Bypass 
The surgical treatment of AS with Aortic Valve Bypass is not a new idea and has 
been around for 45 years. Aortic valve bypass (AVB; apicoaortic conduit) surgery 
relieves AS by shunting blood from the apex of the left ventricle to the descending 
thoracic aorta through a valved conduit (Figure 4). The idea was first conceived by Carrel 
in 1910 (4), performed experimentally by Sarnoff in 1955 (19) and had first clinical use 
by Templeton in 1962 (20). This technique has been almost exclusively used in the high-
risk AS population. 
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FIGURE 4 - Diagram of Aortic Valve Bypass system currently used. Blood is shunted 
from the left ventricle into the descending aorta. 
 
For some high risk patients, more exclusively in the elderly population, AVB is 
an important alternative surgical therapy offering distinct advantages over AVR. The 
main advantages include avoidance of sternotomy, cardiopulmonary bypass, cardioplegic 
arrest, native valve debridement, conduction system injury, aortic cannulation, and aortic 
cross-clamping. Another advantage to clinicians, particularly over percutaneous 
approaches, is the ability to use a known commercially available prosthetic valve with a 
strong track record for durability (21). Surgeons are able to mix and match approved 
valves and components in the assembly of the AVB system to suit the patient and 
procedure used. 
Gammie et al. performed a retroactive chart review of AVB and reported that this 
type of treatment is promising in nature and believe the basic configuration of the system 
to be brain protective (22). Blood flow to the brain comes from the stenotic valve while 
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the rest of systemic flow is delivered from the aortic bypass. Any potential thrombi 
spawned from the prosthetic valve are carried downstream to the descending aorta 
thereby lessening the chances for stroke. Gammie, et al. provided evidence for this in a 
clinical review of AVB (Table II), which demonstrated complete absence of late stoke 
among hospital survivors of the surgery. 
Clinically, the same group has recently achieved very positive results in using 
AVB (3). They found that the mean systolic gradient across the native aortic valve 
decreased from 43 to 10 mmHg and echocardiographically determined conduit flow 
(expressed as a percentage of total cardiac output) was 72%.  Approximately one third of 
blood flow went through the native stenotic valve and two thirds via the conduit. They 
hypothesize that the distribution of blood flow after AVB surgery protects the brain from 
thromboembolism arising from the prosthetic valve because no blood flow to the brain is 
derived from the conduit. They concluded that this may contribute to a decrease in both 
perioperative and long-term stroke risk after AVB surgery compared with conventional 
AVR (3). 
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TABLE II 
REVIEW OF CLINICAL EXPERIENCE WITH AORTIC VALVE BYPASS. 
 
A) Eighteen of 23 done without CPB; 18 of 23 were reoperations; 2 deaths in children with complex congenital problems; 2 deaths in 
patients in cardiogenic shock; 1 technical problem (80-year-old patient with friable ventricle: bleeding contributed to death); used 20 
to 22 mm conduits for adults [22]. B) Both deaths in high-risk patients; left ventricle connector size range 14 to 20 mm [5]. C) 8 late 
deaths; 4 shunt-related (3 disruption of conduit from LV, 1 infection); 26 long-term survivors all asymptomatic, none on 
anticoagulation, none with thrombembolism; in subgroup of patients 65 and older, 6 of 7 were alive and well an average of 5 years 
postoperatively [12]. D) One death due to postoperative sepsis. Patient 2, 19 years out without symptoms, has had two babies; 3 
patient had conduit thrombosis due to heavily calcified tissue valve 6 years out, underwent successful reoperation (valve replacement 
in conduit) and died at 13 years (suicide). Patient 4 required similar valve replacement 3 years postoperatively, now 15 years out and 
doing well [15]. E) All cases done off-pump [11]. F) No thromboembolic complications related to the conduit were observed among 
hospital survivors. 
 
The benefits of AVB over AVR for high risk patients are numerous, though there 
are still potential problems with the operation. Some of these problems include 
pseudoaneurysm, difficulty with the aortic anastomosis in a highly calcified descending 
aorta, kinking of the conduit, and possible dislodgement of LV apical thrombus that was 
not visible in preoperative or intraoperative imaging. The surgeon may also have 
difficulties in the early adoption of this technique. Some of these problems include 
experience trouble with bleeding due to lack of control of the left ventricular apex of the 
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heart and possible use of femoral cardiopulmonary bypass which adds risk of 
embolization. Though as Gammie et al. explain, once the initial learning curve is 
surmounted the surgeon should be able to perform the operation quickly, safely, and 
without the use of cardiopulmonary bypass (3). 
 
Currently Used Design and Materials 
There are 3 typical components used for this operation:  (9) a rigid apical 
connector with a right-angle bend constructed of polypropylene that surrounds a woven 
Dacron graft and is covered with knitted Dacron and includes a sewing ring; (10) a 
prosthetic valve or mechanical valve (stentless porcine valves are the most commonly 
used valves); and (4) a straight woven Dacron vascular graft as shown in Figure 5. There 
are few industry-produced apparatus used for AVB surgery and as such it is often 
common for institutions to mix and match grafts, conduits, and connectors to suit their 
surgical technique. As this technique is further developed and used, further development 
of available materials is expected. Description and commonly used materials of these 
three components are given as following. 
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FIGURE 5 - Diagram of Aortic Valve Bypass system currently used. System consists of: 
A - Elbow apical connector, B – Prosthetic or mechanical valve, C - Straight woven 
Dacron vascular graft. (23) 
 
1) Apical connector – Animal laboratory work done by Brown et al. demonstrated 
that a semi-rigid stent was necessary to prevent progressive narrowing of the apical left 
ventriculotomy (23). Direct application of a prosthetic graft to the apical myocardium has 
been reported and resulted in obstruction at the ventriculotomy site (24). A curved left 
ventricular connector or stent is supplied in sizes from 12 to 22 mm by Medtronic, Inc., 
(Figure 6). 
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FIGURE 6 – Right angle apical connector manufactured by Hancock- Extracorporeal 
(Hancock, Medtronic Inc., Minneapolis, MN) (25). 
 
The connector was developed in the early 1970s by Hancock- Extracorporeal 
(Hancock, Medtronic Inc., Minneapolis, MN) for Brown, et al., (20) and has been 
continually supplied since that time. It was originally supplied in both straight and angled 
configurations, though is routinely used as the right-angled connector for aortic valve 
bypass done through a left thoracotomy. The 90° angle in the stent prevents kinking of 
the conduit. The apical connector is designed to project 3 to 10mm into the cavity of the 
left ventricle. It is lined with a low-porosity woven graft and its external surface is 
covered with a more porous graft material to promote tissue ingrowth (23).  
 
2) Prosthetic or mechanical valve – Either type of valve may be used, and their 
usage depends on the institution performing the operation. Due to widespread use and 
development of AVR, the design and safety of replacement aortic valves have been 
refined and improved for decades. The sizes range from 17 to 23mm as appropriate to the 
patient and procedure. Currently, the valves used in most institutions for AVB are 
prosthetic with the most common being the stentless porcine valve. The advantages of 
prosthetic valves lie in the postoperative treatment of patients. Mechanical valves require 
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anticoagulation drugs, such as Coumadin, which increase the risk for stroke. With use of 
prosthetic valves, physicians can treat patients postoperatively with just aspirin. 
It is also possible to obtain valved conduits on the market that simplify the work 
of the surgeon as the valve and the vascular graft are preassembled. Currently, the only 
FDA approved commercially available valved conduit is manufactured by Medtronic, 
Inc. (Minneapolis, MN) seen in Figure 7.  
 
FIGURE 7 – Example of valved conduit used in the AVB system produced by 
Medtronic, Inc (25) 
 
The conduit contains a stentless porcine aortic valve that is glutaraldehyde 
preserved and has an estimated valve area of 3 cm2. It comes in sizes of 12 to 22 mm in 
diameter, which can be used for almost any size patient. The valve in the conduit is 
positioned between the proximal and middle third of the conduit. This position of the 
valve allows room for placement of vascular clamps, when or if the conduit valve 
replacement is needed in late follow-up. (23)  
3) Straight woven Dacron vascular graft – Awoven Dacron graft produced by 
Hemashield, Boston Scientific, Natick, MA is the most commonly used graft  Surgeons 
use this graft material for many different clinical applications, including shunts, valves, 
and cannula (25). The length and size of the graft is custom suited to the patient. 
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Current Implantation Technique 
Implantation of the AVB conduit system is commonly performed through either a 
median sternotomy or lateral thoracotomy. The left thoracotomy is the most common 
approach , particularly if the patient has had prior sternotomy(s). The thoracotomy 
procedure has been well described by a number of physicians (5,23,24). The procedure 
can be done without crossclamp and hypothermic circulatory arrest, and requires 
markedly less time on cardiopulmonary bypass. Most importantly, the risk of 
perioperative stroke is significantly reduced decreased (25). 
A currently used ‘off pump’ procedure, as described by Vassiliades (5), uses an 
18-gauge needle inserted through the left ventricular apex. A guide wire and a series of 
dilators are then applied to the ventricular apex and a 14 Fr occlusion balloon is inserted 
over the wire. A ventricular coring device is then threaded in-line over the catheter, and 
the apical core is removed. The balloon occludes the apical opening in the ventricle while 
the connector is slid into place. The occlusion balloon is left in place while sutures are 
sewed from the ventricular muscle around the opening in the apex to the external cuff of 
the connector. The distal end of the apical connector is then sewed to the valved conduit 
and de-aired (5). 
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IV. DESIGN AND CONCEPT 
 
Evaluation Process 
As previously discussed, the aortic valve bypass system is favored by many 
clinicians due to the established track record of their individual components (i.e. graft, 
valve, apical cannula). Specifically, prosthetic valves have a long history and have been 
successfully used clinically for decades. In contrast, the apical cannula used for AVB has 
not been extensively studied. The design of the current apical connectors is an adaptation 
from a design primarily used for complex congenital left outflow tract obstruction in 
children (3). As such, optimization of the design of the apical cannula could improve 
flow characteristics of the entire system. 
There are a number of important evaluation criteria when developing the apical 
cannula (Table III). These important design points include the size of the conduit, 
biocompatibility, optimal tip design, surgical insertion technique, stagnation points, and 
blood hemolysis/shear stresses. Other important design criteria include the type of blood 
flow, amount of retrograde flow, and adequate blood flow to the aortic arch head vessels. 
The upper and lower limits for the size of the cannula are governed by two 
factors. The upper limit is defined by the surgical insertion technique used. The lower 
limit is the smallest size that will allow adequate blood flow through the conduit with low 
aortic valve pressure gradient. To discern these design end-points, a series of in vitro 
experiments with a mock circulation flow loop were conducted, which were then 
validated in a computational flow dynamic (CFD) model.   
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TABLE III 
DESIGN CRITERIA FOR THE DEVELOPMENT OF THE APICAL CANNULA 
 
 
It is important to have a large enough inlet diameter to allow for ample flow of 
blood through the conduit. It is helpful to imagine the system in terms of an electrical 
circuit to better understand the important factors in this analysis (Figure 8). In aortic 
stenosis, the resistance of the aortic valve is greatly increased and in response the flow 
rate decreases and AV pressure gradient increases. The AVB system creates another 
parallel path in the circuit. The total resistance of the aortic valve with the conduit is 
much less than the resistance of the stenotic aortic valve. The goal of the AVB system is 
to return the total resistance to normal levels so that the pressures and flow rates can 
return to normal physiologic conditions.  
 
Experimental Design Criterion Dynamic 
Flow
Static 
Flow
Blood 
Trauma
Size of the conduit X X X X
Biocompatibility of materials X X
Optimal tip design X X X X
Stagnation areas / eddies (thrombosis) X X
Blood Shear Rate / Hemolysis X X
Type of flow (laminar or turbulent) X
Amount of retrograde flow X X
Flow to coronaries and head vessels X X
Surgical Insertion Technique X
Mock Flow Loop Computational 
Fluid Analysis 
(CFX)
Animal 
Model 
(bovine)
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FIGURE 8 – AVB system shown as an electrical circuit. Left – the left ventricle is 
represented as the voltage source with the aortic valve and AVB conduit being 
represented with a switch and resistance (Rav and RAVB). The basic relationships between 
the systems are shown in upper right table. The total resistance of Rav and RAVB in 
parallel in the aortic valve bypass model is much less than the resistance in the aortic 
stenosis model. 
 
It is also important to find the point of highest resistance in the AVB system, as 
this will ultimately be the critical design feature of the device. In this case, the point of 
highest resistance may lie at the narrowest portion of the conduit, which in the current 
system is the cannula inserted into the left ventricle. The cannula is the narrowest point in 
the AVB system because it offers the most benefits in terms of decreased surgical risk. 
As such, the diameter should be as small as possible while still delivering enough blood 
to decrease the total resistance back to near normal values. 
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Preliminary Cannula Prototype 
A preliminary prototype was fabricated and tested for feasibility of concept. A 
mock circulation flow loop model was used to investigate the efficacy of the AVB 
design. Observations and data from these experiments were instrumental in the creation 
of a final, proposed design. The inflow cannula was constructed of Pyrolytic Carbon 
(PYC) and measured 7cm in length with 10 mm outer diameter at the cannula interface 
that tapers to 7 mm outer diameter at the tip. The prototype was based in part on designs 
used in pediatric cardiopulmonary bypass venous cannula and was modeled with the use 
of CAD modeling (AutoCad 2006). Figure 9 shows the preliminary prototype CAD 
drawings, 3D model, and pictures of the fabricated cannula. The cannula has an open tip 
design with 12 side holes to allow for rapid flow of blood from the left ventricle into the 
descending aorta. 
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FIGURE 9 - Schematics, 3D models, and picture of preliminary prototype fabricated. A) 
Drawing of model showing dimensions and sectioned view of the cannula, B) 3D model 
of design (AutoCAD 2006). C) Fabricated cannula fabricated of pyrolytic carbon using a 
proprietary method (ATS Medical). 
 
Fabrication 
 The fabrication utilized a proprietary rapid-prototyping manufacturing process 
(ATS Medical; Minneapolis, MN). The fabrication process creates a strong, brittle 
ceramic design with a high modulus of elasticity. It has been shown that thermal 
treatment of pyrolytic carbon at temperatures above 3000°C results in the formation of 
blocks having a mosaic sub-structure, which cause a reduction in the azimuthal 
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disorientation of carbon produced at a temperature higher than 2000°C in a vacuum, 
corresponding to the structure of amorphized natural carbon. 
 
Pyrolytic Carbon 
Biocompatibility of implanted materials has been a concern for clinicians due to 
the many possible complications, including infection and rejection from the body. 
Pyrolytic Carbon (PYC) has been one of the most successful implantable biomaterials, 
having been utilized in millions of medical devices worldwide. In other medical 
applications, such as heart valves and orthopedic joints, PYC has high durability, 
strength, and resistance to wear, while also exhibiting excellent biocompatibility and 
thromboresistance. Today, PYC remains the most popular material available for artificial 
mechanical heart valves, being used to produce over 4 million devices of 25 different 
designs.  
PYC was chosen as the fabrication material for the cannula due to these 
biocompatibility properties. Slaughter et al. have presented experience with a new type of 
proprietary surface modification known as “ForcefieldTM” (ATS Medical) (6). Details of 
this experiment are given below. This modification was not used in testing the cannula in 
this report, though this unique property was a factor in choosing PYC for prototype 
fabrication. 
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“Forcefield” surface modification 
The Forcefield surface alteration uses an electrostatic charge in conjunction with 
protein adsorption from blood to create a biocompatible blood interface that resists 
platelet adhesion. A small charge is applied to the experimental PYC over a short 
duration in a proprietary process (ATS Medical).  A section of PYC with the applied 
‘forcefield’ was tested clinically in a cardiopulmonary bypass circuit (CPB) circuit in six 
patients and showed a significant reduction in platelet adhesion and activation under 
scanning electromicroscopy (SEM) as seen in Figure 10.  
Patients undergoing a coronary artery bypass graph (CABG) operation are 
exposed to both a control and ‘Forcefield’ modified PYC sample in an experimental 
section of the CPB tubing used in perfusion during cardioplegia. The results obtained 
from that study show the potential for an increase in biocompatibility, as well as 
improvement in thromboresistance for PYC. (6)  
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FIGURE 10 - SEM photos of platelet aggregation on “Forcefield” modified PYC and 
control PYC samples. The top images show clear platelet activation and spreading across 
the PYC while the bottom images show non-activated (round, non-attached) platelets. 
The ‘Forcefield’ technology is an important tool used to increase the biocompatibility of 
the cannula. 
 
The mechanism(s) behind the non-activation of the platelets on the PYC is still an 
area of debate among researchers. This unique property of PYC is still not fully 
understood and warrants further study. For the purposes of this report this ‘forcefield’ 
surface modification was not used as it is outside the main design features being studied. 
However, this technology appears promising and will be incorporated into future 
experiments. 
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‘Seldinger’ Insertion Technique 
The current AVB technique commonly uses a 20mm diameter conduit that is 
secured through an apical connector during bypass, or more commonly during an off 
bypass technique as described previously. One of the main drawbacks is the coring of the 
apex and use of a balloon pump to make a large enough opening to allow for suturing of 
the apical connector. Often this adds surgical time and risk. To overcome these obstacles, 
a Seldinger-like insertion technique is proposed for use with the cannula. The smaller size 
of the cannula allows for this type of surgical implantation. 
   The Seldinger technique is a medical procedure to obtain safe access to blood 
vessels and other hollow organs. It is named after Dr. Sven-Ivar Seldinger, who 
pioneered the procedure in 1953 (26). It is mainly a technique used for angioplasty, 
though the same principles will be used in the insertion of the cannula. The implantation 
will employ a small incision at the apex of the heart followed by introducers and dilators 
to make an opening large enough for the cannula. The cannula is then secured through 
use of a locking ring mechanism sutured on the heart. The main advantage of this type of 
technique is avoidance of coring the heart and makes rapid implantation possible. Further 
development of the technique and implantation tools will need to be completed in future 
work. 
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FIGURE 11 - Inflow cannula (A) designed to simplify and shorten the ventricular apical 
implantation procedure by using the Seldinger technique at the apex of the left ventricle 
(B). The conduit is then attached to the descending aorta (C). This approach eliminates 
the need for placing the patient on cardiopulmonary bypass, avoids ventricular coring, 
and achieves hemostasis through a small apical sewing ring and locking mechanism. 
 
Figure 11 shows early, non-published work, of an implantation feasibility study 
by Slaughter et al. in a bovine model using the preliminary cannula prototype. This 
implantation uses a stab incision with rapid insertion of the cannula into the ventricle. 
This work showed that this type of implantation is very promising as there was minimal 
bleeding and complications seen at the insertion site. The cannulation system simplifies 
the surgical procedure and potentially minimizes morbidity/mortality to promote faster 
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recovery.  Anticipated benefits of this approach may include rapid application of therapy 
with reduced operative time and shorter hospital length of stay. 
 
V. EXPERIMENTAL DESIGN AND METHODS 
 
 Three mock flow circulation and CFD analysis was performed on a series of 
cannulas to investigate the flow properties. The mock flow loops were a Static Flow 
Loop, Dynamic Flow Loop, and a Blood Trauma Loop.  
 
Static Flow Loop 
The static flow mock flow loop was utilized to determine the flow versus pressure 
drop relationship for different size cannula under constant conditions. Seven different 
return venous cannulas were tested for flow characteristics using two variables, type and 
size of the tip. The cannulas were obtained from expired or surplus cardiopulmonary 
bypass equipment from surplus supplies at the Cardiovascular Innovation Institute. The 
aim of this experiment was to hold as many of the variables constant (pressure drop, 
velocity) as possible so that differences can be inferred between the cannula types. The 
experimental system is shown in Figure 12 and is composed of:  
 
 
32 
 
 
FIGURE 12 – Static Loop used for analysis of flows for different sized cannula under 
static and continuous pressure drop conditions composed of: A) Reservoir, B) Flow Loop 
C) DAQ system D) HeartMate II VAD system monitor. 
 
 While holding the pressure drop at a constant value, the flow rate was measured. 
Figure 13 shows the flow path of the static loop. Plasma-Lyte (Baxter Laboratories) was 
used for fluid flow in the static loop. Plasma-Lyte has the same viscosity as water and is a 
closer substitute to actual blood plasma than pure water. The tubing was standard 3/8 x 
3/32 class VI CPB tubing commonly used in open heart procedures (COBE 
Cardiovascular, Inc. Arvada, Co). The test section was composed of a small section of 
clear silicone tubing with an injection port for the inlet pressure catheter upstream from 
the test cannula. 
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FIGURE 13 – Static Flow loop. The white arrows show the path of the flow from the 
reservoir to the HeartMate II through the test section and finally out back to the reservoir. 
High fidelity Millar catheters were used to measure the Pre-VAD, Inlet and Outlet 
pressure. A Transonic flow probe was used to measure the flow rate. A calibration 
chamber was used to take pre and post calibration measurements. 
 
 The test catheter was inserted into the test section of the static loop so that the 
head of the cannula was completely surrounded by fluid as shown in Figure 13 (bottom, 
right). 150mL was chosen for the volume of the test section as this is the approximate 
volume of the left ventricle at the end of the systolic period and is when the cannula will 
experience the highest flow rates. 
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 The pressure drop across the cannula was created by a small rotary pump, the 
HeartMate II (HMII) ventricular assist device. The only controlled variable of the 
experiment was the pump speed (revolutions per minute, rpm) of the HMII. In this way, 
the pressure drop was controlled and the flow rates for the cannula were directly 
compared. The pressure drop was defined as the difference between the inlet and outlet 
pressures measured by high-fidelity pressure catheters (Millar Instruments, Houston, 
TX), while the flow rate was determined by a transit-time flow probe (Transonics, Ithica, 
NY) at the distal end of the cannula. 
Each cannula was tested over the HMII operating range of 6,000 to 15,000 rpm 
with pressure and flow measurements recorded at 200 rpm increments. Five second 
epoch data files were collected utilizing the DAQ system at every 1,000 rpm for post-
processing and analysis. Data was collected once the static loop had reached a constant 
value for flow after an increment change. The return reservoir bucket was kept at the 
same height and the tubing components were confined to the same path for each run. 
After each cannula was tested the loop was filled with Plasma-Lyte back to the same 
volume (2,000 ml). Data was then analyzed and plotted with MATLAB and EXCEL 
software packages. 
 The resistance was obtained through a simple regression analysis. The slope of a 
linear model can be used as a close approximation of the true resistance. The R-Squared 
value was used to determine the accuracy of the resistance. This value ranges from 0 to 1 
where a value of 1 represents a perfect fit. This is calculated using the following equation 
where SSerr = sum of squares of the residuals and SStot = the total sum of squares value. 
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The cannulas ranged from 9.3 - 12mm in outer diameter (28 Fr to 36 Fr) and were 
arranged into three groups based on the design features of the tip at the end of the 
cannula. Table IV provides the measurements taken from each cannula as well as the 
manufacturer of each. The surface area of the opening was approximated and measured 
using calipers. The cross sectional area was calculated by measurement of the inner 
radius of the cannula. Figure 14 shows the three types of tips that were classified based 
from the distinguishing characteristics as Cage, Open, or Dome. 
 
TABLE IV 
CHARACTERISTICS OF CANNULA TESTED 
 
 
Type
Outer 
Diameter Size 
mm, (Fr)
Inner 
Diameter 
mm
Cross Sectional 
Area (CSA) 
mm^2
Surface Area of 
Openings (SA) 
mm^2
Manufacturer 
Cage 9.3 (28) 6.5 33.2 47.4 Sarns
Open 9.3 (28) 6.7 35.3 42.0 Research Medical Inc
Dome 10 (30) 7.4 43.0 111.0 Terumo
Open 10 (30) 7.5 44.2 153.5 Medtronic
Cage 10.7 (32) 7.5 44.2 69.5 Sarns
Dome 11.3 (34) 8.8 60.8 144.9 Sarns
Cage 12 (36) 8.8 60.8 74.0 Sarns
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FIGURE 14 – The seven cannula used separated by type and size of tip. The Cage type is 
distinguished by 4 main holes at the tip formed resembling a cage. The Open type 
features an open orifice at the tip with eight sideholes arranged on the head of the 
cannula. The Dome type features a smooth dome tip with eight sideholes arranged around 
the head of the cannula. 
 
  
Blood Trauma Loop 
 To test for possible trauma and damage to blood cells caused by high shear rates 
in the cannula, a static flow test using bovine blood was used. The preliminary prototype 
cannula was tested in a mock loop with a continuous flow pump (HeartMate II). The 
circuit consisted of a 500 ml reservoir, 23cm of standard PVC uncoated tubing, 40 
micron inline filter, transonic flow probes and pressure transducers as seen in Figure 15.  
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FIGURE 15 – Flow loop used in blood trauma data. A) 500mL reservoir, B) Testing 
section, C) HeartMate II continuous flow VAD. 
 
Fresh whole bovine animal blood was collected and stored for less than 48 hours 
for performance testing. To minimize the effects of blood variation for tests run with the 
cannula, a sufficient amount of blood (5-6 liters) was drawn from a single animal to 
permit testing. Blood hemolysis testing followed ASTM international standard F1830 
(27). Data collection consisted of blood hematology: white blood cell, red blood cell, 
platelet, hemoglobin, hematocrit, and plasma free hemoglobin (WBC, RBC, PLT, HgB, 
HCT, PF-HgB). Pump performance (rpm’s and flow rates) and mock circuit status 
(pressure inlet/outlet, delta and measured flow rates) were also taken. 
 The testing conditions were held for at a constant range with the pump operating 
at 8400 rpm for the length of the experiment. These test conditions created a pressure 
drop of 40mmHg with a constant flow rate of 2.4 lpm. Baseline readings were recorded 
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and samples were taken at intervals of 90 minutes for a total of 6 hours. Pressure and 
flow measurements were taken from the pressure catheters and Transonic flow probes in 
the flow loop. Complete blood chemistry profiles and blood gases were measured with 
Gem 4000 (Instrumentation Laboratory, Warrington, UK).  Cell counts were measured 
with HemaVet 950FS (Drew Scientific, Inc., Dallas, TX).  Plasma free hemoglobin was 
measured using a HemoCue Plasma/Low Hb Photometer (HemoCue, Inc., Lake Forest, 
CA) shown in Figure 16. 
 
FIGURE 16 – HemoCue Plama/Low Hb Photometer used in the trauma study to measure 
plasma free hemoglobin. 
 
In compliance with clinical guidelines for VADs (FDA and ISO 7199), blood was 
anticoagulated with heparin (4500 units per liter of blood) (28).  A minimum Activated 
Clotting Time (ACT) of 300s was maintained with additional heparin as needed. To 
simulate dilution during bypass, the blood was diluted with normal saline to a hematocrit 
of 25 ± 3% for the testing. 
Figure 17, Left shows the in vitro flow loop used for the preliminary prototype; 
on the Right, the preliminary prototype is inserted into a small silicone o-ring that models 
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the Seldinger implantation technique that uses a stab wound to introduce the cannula into 
the apex of the left ventricle. Similar to the static flow mock loop experiment, this study 
used the HeartMate II continuous flow VAD, in this case set at a constant speed of 8400 
rpm.  
 
FIGURE 17 – LEFT: Bovine blood flowing through a mock flow loop consisting of A) 
500mL Reservior, B) Standard 23cm CPB tubing, C) HeartMate II Controller, D) 
HeartMate II continuous flow VAD, E) Transonic Flow Probe and Pressure Catheter 
inside injection port. RIGHT: Preliminary Prototype inserted inside the tubing simulating 
the insertion technique used for implantation. 
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 The flow rate was kept at a constant 2.4 lpm over the course of the 6 hour study. 
Heparin was administered throughout the course of the study to maintain a constant ACT 
greater than 300 seconds.  Also blood samples were taken from the circuit every 90 
minutes for blood analysis and heparin was added throughout the study period which has 
a slight dilution effect.  
 
Dynamic Flow Loop 
 The dynamic flow loop study was used to investigate the flow characteristics of 
different size cannula under simulated physiologic pressure and flow conditions. A mock 
flow loop of the adult systemic circulation was used to test the AVB system. Three 
cannula were tested: 1) Prototype design, 2) 32Fr Sarns Venous Return cannula, and 3) 
36Fr Sarns Venous Return cannula. The tip design of the three cannulas are very similar 
(open distal orifice with sideholes along body of the tip) so the effect of cannula size on 
physiologic conditions was the goal of this study.   
 The test conditions included a baseline with the AVB system clamped off from 
the loop, the AVB system under normal physiologic conditions, and the AVB system 
under three different aortic stenotic conditions (mild, moderate, and severe). High fidelity 
pressure catheters (Millar Instruments, Houston, TX) and transit-time flow probes 
(Transonics, Ithica, NY) were used measure simulated cardiovascular pressures and 
flows.  For each test condition, 15 second data files were recorded using the DAQ 
system.  
 Each cannula was inserted into the apical cannulation port at the apex of the mock 
ventricle. The cannula was connected to a 19mm graft and mechanical valve conduit, 
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which was connected to a T-junction on the mock descending aorta that completed the 
AVB circuit. Glycerol was used for a blood analog with a viscosity of 3.7 centipoise, 
similar to that of blood. The flow loop was instrumented to record the following 
hemodynamic parameters: 
 Aortic Flow (AoF) 
 Aortic Pressure (AoP) 
 Left Ventricular Pressure (LVP)  
 Left Atrial Pressure (LAP)  
 AVB conduit Flow (GRF) 
 Pressure inside the AVB conduit (GRP) 
 
 Aortic stenosis was simulated in the mock loop by applying a clamp to the mock 
aortic root. Baseline data was taken where the AVB conduit was clamped off from the 
mock loop at the apex and the descending aorta. With the AVB conduit unclamped, four 
different AVB configurations were tested: 1) No aortic stenosis under normal 
physiological conditions, 2) Mild aortic stenosis, 3) Moderate aortic stenosis, 4) Severe 
aortic stenosis. The peak-to-peak pressure difference (peak LVP – peak AoP) was used to 
quantify the pressure drop across the valve and assign the degree of aortic stenosis. Table 
IV provides the testing conditions used for this study (Table V, Left) and the 
transvalvular pressure differences used to simulate aortic stenosis (Table V, Right) as 
outlined ACC/AHA Practice Guidelines. 
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TABLE V 
TESTING CONDITIONS FOR THE DYNAMIC FLOW STUDY. 
 
 The experiments were completed at the Cardiovascular Innovation Institute. The 
mock loop was tuned to the testing parameters through adjustment of the vascular 
resistance and compliance. The degree of aortic stenosis was controlled through 
adjustment of a resistance clamp at the aortic root. After the loop had reached a stable 
condition, a 15 second data file was taken on the DAQ system. The testing protocol for 
cannulas tested was as follows.  
1. A baseline reading was taken with the AVB circuit clamped off from the mock 
loop, which had been tuned to the testing conditions listed in Table V. 
2. The resistance clamp at the aortic root was adjusted until the transvalvular 
pressure difference matched the desired value (none, mild, moderate, or severe) 
and a baseline reading was taken. 
3. The AVB circuit was unclamped and a data file was taken after the system had 
reached stability. 
4. Steps 2 and 3 were repeated until all four of the AVB configurations were 
completed 
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5. The aortic root was then fully occluded with all flow going through the AVB 
conduit and a data file was taken. 
6. A post calibration file was taken with a static circuit where the pump was turned 
off and all clamps removed. 
7. The cannula was removed from the circuit and the next cannula was placed in the 
circuit for testing. 
 
Table VI provides the size of the cannulas, valve, and graph used as well as 
photos of the tips of the cannula. The venous cannula used had ‘open’ tip shape with an 
open orifice at the distal tip and eight sideholes along the body of the tip. 
 
TABLE VI 
CANNULA CHARACTERISTICS 
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The data files from the study were first analyzed in using the HEART program 
using MATLAB. Each file was picked on a beat-to-beat basis and systolic pressure peaks 
were chosen from the plots. Mean aortic flow, distal aortic flow, conduit flow, aortic 
pressure, conduit pressure, left ventricular pressure, and left atrial pressure (AoF, AoFd, 
GRF, AoP, GRP, LVP, LAP; respectfully) values were calculated. The valve gradient 
was calculated from the peak AoP and LVP pressures. Total % Conduit flow was 
calculated using the AoF, Aofd, and GRF. Appendix II provides the data obtained and 
two sample plots that were beat picked. A total of 37 data files were collected. 
 
Computation Flow Dynamic (CFD) Analysis 
 Computational flow analysis was used to investigate the effects of design features 
of the cannula tip, specifically the number and size of the sideholes on the cannula. The 
wall shear stresses, shear strain rate, and flow rate were calculated through simulation in 
the ANSYS CFD (ANSYS Inc., Canonsburg, PA, U.S.A.) software package. Differences 
in these parameters between cannula designs were used to evaluate flow characteristics.  
The CFD analysis was broken into two main studies: Number of Sideholes and Size of 
Sideholes. 
 The CAD models were created using SolidWorks (SolidWorks SP3.0, Dassault 
Systèmes; Vélizy, France) CAD software and are similar in design to the preliminary 
prototype. A larger view of a typical CAD model for both the cannula and the mesh 
model can be seen in Appendix III. The cannulas created for the CFD analysis were all 
12mm in diameter and identical to each other with the exception of the number and size 
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of the sideholes. Through this method, the characteristics of the sideholes design could be 
directly studied.  
 The CAD files of the cannula designs were loaded into ANSYS workbench 
project and the 3D models were checked for continuity. The model was then meshed 
using the AutoMesh function (Figure 18) with the appropriate settings for fluid flow. A 
fine relevance center sizing was used to ensure ample node and element creation around 
those parts of the geometry which have finer detail. The meshes were visually verified for 
the proper geometry. Mesh statistics for each cannula are presented in Tables VIII and IX 
in the following sections. 
  
 
FIGURE 18 – The meshing program for ANSYS CFD software analysis. A medium 
density mesh was chosen for this analysis. 
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 Pre-solver software was used to define boundary regions and initial conditions. 
Figure 19 shows the defining of the boundary regions and is used to set up the running 
parameters. A cylinder (radius = 15mm, length = 50mm) was placed around the cannula 
body was used for the inlet boundary region. This allows for development of flow into 
the cannula and will allow for more accurate streamlines and vector fields around the 
cannula orifices.  
 The cylinder is placed only around the areas of the cannula that will be inside the 
left ventricle and models in vivo-like conditions. The inlet boundary allows for flow to 
originate from all sides of the cannula. In this way the wall shear stress and strain can be 
measured for all blood contacting portions of the cannula. 
 
 
FIGURE 19 – Defining the boundary regions and initial conditions for the cannula in the 
Pre-solver component software.  
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 Simulation operating conditions are presented in Table VII. A constant pressure 
boundary condition with a pressure difference between inlet and outlet of 6 mmHg was 
assumed. The operating fluid, blood, was assumed to be a Newtonian fluid with a density 
of ρ = 1.1 g/cm3 and viscosity ν = 0.035 Poise. Flow was not assumed to be laminar as a 
k-ε turbulence model was used. 
 
TABLE VII 
SIMULATION OPERATING CONDITIONS 
 
  
 The constant 6mmHg pressure boundary represents the peak systolic trans-
conduit pressure gradient and is based from clinical hemodynamic data (29). Vliek et al. 
reported hemodynamic data for AVB intraoperative surgery with a median peak gradient 
between the left ventricle and distal conduit in 18 patients (2 with 16-mm apical 
connectors, 6 with 14-mm apical connectors, and 12 patients with 12-mm apical 
connectors) as measured directly in the operating room of 5.6 +/- 3.8 mmHg (range, 0 to 
14 mmHg).  
Fluid Type Newtonian
Density 1.1 g/cm^3
Viscosity 0.035 P
Turbulence Model k epsilon
Boundary Condition Constant Pressure
Pressure Gradient 6 mmHg
CFD Simulation Conditions
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  Examination of the Reynolds number is an important factor in CFD analysis and 
was measured at the cannula outlet. This is a dimensionless number that gives a measure 
of the ratio of inertial forces to viscous forces defined as Re = U * D/ν (where U is the 
average velocity through the orifice, D is the orifice diameter, and ν is the average 
kinematic viscosity of blood). Application of this number though is also dependent on the 
type of opening. Threshold Reynolds number for turbulent flow is markedly lower 
(approximately 800) for flow through an orifice, whereas it is higher (around 3,000) for a 
pipe (in this case, a conduit).  
 The CFX solver ran until the solving equations converged to a final solution. The 
post-solver component was then used to analyze and visualize the results. Stream lines, 
gradient profiles, vector fields, and slice planes were used for visual analysis while 
average, peak, and minimum values for various parameters such as flow rate, pressure, 
shear rate, and velocity at the boundary regions were calculated. A custom results report 
was generated to obtain desired statistics, figures, and data from the simulations. An 
example of the one of these reports can be seen in Appendix IV. 
   
Number of Sideholes Study 
 This study compared four different 12mm diameter (36Fr) cannulas for 
differences in flow characteristics based on the number of sideholes on the tip of the 
cannula. This group was comprised of cannula with: No sideholes, 4 sideholes, 8 
sideholes, and 12 sideholes. Figure 20 gives the CAD models of each of the four models 
as well as the model used for meshing and CFD analysis. The cannulas were identical to 
each other with only differences being in the number of sideholes each one featured.  
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FIGURE 20 – The CAD models for the number of sideholes CFD study. Both the 
cannula design (left) and the model used for meshing and CFD analysis (right) are shown 
for the four different models. 
 
 The sideholes on all the cannula in this study were the same size, having an oval 
shape with a radius of 3mm and an area of 46.6mm2. This shape and size was chosen as it 
is similar to sidehole designs used in the cannulas studied in the mock flow loop 
experiments. Table VIII provides the mesh characteristics, surface area, and volume for 
each cannula.  
TABLE VIII 
MESH CHARACTERISTICS. 
 
None Four Eight Twelve
Nodes 68346 149169 226986 297412
Elements 370144 814855 1241999 1629111
Area (m^2) 3.34E-03 3.21E-03 3.08E-03 2.95E-03
Volume (m^3) 3.65E-05 3.67E-05 3.68E-05 3.70E-05
Number of Sideholes
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Size of Sidehole Study 
 Similar to the number study, the objective of the size study was to determine 
differences between 12mm diameter (36Fr) cannula that have different sized sideholes. 
Four cannulas with eight sideholes of varying sizes were tested. Figure 21 shows the 
cannulas tested which featured small, medium, and large sideholes of the same shape. A 
fourth cannula featured the same size sideholes as the medium cannula but did not have 
the 0.5mm fillet used on all the edges of the openings. This cannula was used to compare 
the effect that fillet geometry had on flow. 
 
 
FIGURE 21 – The CAD models for the size of sideholes CFD study. Both the cannula 
design (left) and the model used for meshing and CFD analysis (right) are shown for the 
four different models. 
 
 The medium size cannula features the same size sideholes that were tested in the 
number of sideholes study. The large size cannula had sideholes that were twice the area 
of the medium, while the small cannula had sideholes that were half the area of the 
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medium cannula. This provided a nice range of sizes for comparison purposes. The sizes 
of the sideholes are presented in Table IX. The radius of the oval shape and total area are 
given, as well as the mesh characteristics, surface area, and volume for each cannula.  
 
TABLE IX 
AREA OF SIDEHOLES AND MESH CHARACTERISTICS 
 
  
 
 
VI. INSTRUMENTATION AND EQUIPMENT 
 
 
 Experiments were performed at Cardiovascular Innovation Institute on the 
University of Louisville medical campus in Louisville, KY and the Biologic Resources 
Laboratory at the University of Illinois at Chicago. Experiments were carried out with the 
assistance of Cary Woolard and Michael Sobieski under the supervision of Dr. Steven 
Koenig and Dr. Guruprasad Giridharan. The following equipment and materials was 
used in the design, testing, and analysis of the cannula: 
Small Medium Large No Fillet
Radius (mm) 1.92 3 4.56 3
Sidehole Area (mm^2) 23.13 46.26 92.52 46.26
Nodes 200796 226986 257983 82636
Elements 1095191 1241999 1417062 448047
Area (m^2) 3.24E-03 3.08E-03 2.80E-03 3.17E-03
Volume (m^3) 3.67E-05 3.68E-05 3.70E-05 3.68E-05
Size of Sideholes
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 Data Acquisition System 
o Measurement Instrumentation 
 Millar high fidelity pressure catheter 
 Transonic Flow probes 
o Instrumentation Rack 
o Data Acquisition Software 
 LabVIEW (National Instruments, Austin, TX) 
 Mock Flow Apparatus 
o Continuous Flow 
 Static Flow Loop 
 Blood Trauma Study 
o Dynamic Flow 
 Adult Circulation Mock Flow Loop 
 Computer Software Packages 
o Data Analysis 
 MATLAB (The MathWorks, Inc., Natick, MA) 
 Microsoft Excel 
o Computer Aided Design (CAD) 
 SolidWorks (SP3.0 2009, Dassault Systems) 
 AutoCAD (AutoCAD 2008, San Rafael, CA) 
o Computational Fluid Dynamic (CFD) 
 ANSYS CFX (ANSYS Inc., Canonsburg, PA, U.S.A.) 
 
 
Data Acquisition System (DAQ) 
 Pressure catheters, flow probes, and the DAQ system was used to measure, 
visualize, and store data collected from mock flow loop experiments completed. The 
DAQ system was used for all experiments to test the design of both the initial and final 
prototypes. 
 
Measurement Instrumentation 
Two different types of pressure catheters and flow probes were used in the flow 
experiments performed. A high fidelity, dual pressure–volume conductance catheter 
Millar Instruments, Houston, TX) was used for simultaneous mock ventricular pressure, 
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ventricular volume, and aortic pressure measurements in the dynamic loop. Single tip, 
high fidelity catheters (Millar Instruments, Houston, TX) were inserted into introducer 
ports for measuring pressures in both static and dynamic flow loops. Flow was measured 
with clamp and in-line, transit time flow probes (Transonics, Ithaca, NY) were also used 
in both experiments. Pressure and flow transducers were calibrated before and after to 
verify gain and offset accuracy.  
 
Instrumentation Rack 
The instrumentation rack was composed of transducers, amplifiers, and signal 
processors. This custom built clinically approved Good Laboratory Practices (GLP) 
compliant DAQ rack is described in Koenig et al. (30) and was used to collect and store 
data from the mock loop studies shown in Figure 22. Signal conditioning was completed 
using transducer amplifiers (Ectron, San Diego, CA), a transit time flowmeter 
(Transonics, Ithaca, NY), a volume conductance unit (Leycom, Sigma V, Netherlands), 
and other peripheral conditioners integrated into the instrumentation system. Signal 
conditioned data were low pass filtered at 60 Hz, analog to digitally converted (AT-MIO-
16E-10 and LabVIEW, National Instruments, Austin, TX) at a sampling rate of 400 Hz, 
and stored on a personal computer (7). 
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FIGURE 22 – DAQ system used to collect and store data from the mock flow loop 
studies used to characterize the cannula (30). 
 
This DAQ system allows the user to connect a variety of instrumentation and then 
condition, amplify, and process the signals. A 16-channel signal conditioning and 
distribution unit is used to drive multiple peripheral monitoring and recording devices.  
The DAQ system has fixed gain and offset control to maximize A/D input range of 
peripheral devices, and low-pass filters to remove electrical noise and prevent aliasing. 
An analog to digital converter then allows for data storage. Signals from pressure 
catheters and flow probes are amplified and conditioned and are seen real-time on the 
monitor. Further detail concerning the components, construction, and operation of the 
DAQ unit is outlined in Koenig et al. (30). 
The software used to for data acquisition is also a custom built LabVIEW 
(National Instruments, Austin, TX) described by Drew et al. (31,32). This graphical 
55 
 
oriented program gives users a plethora of tools to aide in the capture and analysis of 
data. The Cardiovascular Data Acquistion Software (CDAS) program developed by this 
group allows for custom setup for the 16 channel DAQ system. After the user has set up 
the desired profile, the program is run and allows for real-time display of waveforms 
collected from experiments. Figure 23 shows a layout of real-time waveform collection 
and GUI. 
 
 
FIGURE 23 – The DAQ system allows for real-time monitoring and collection of data 
from waveforms produced from pressure and flow transducers (30). 
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Adult Circulatory Mock Flow Loop 
In order to study the flow characteristics of the cannula under physiological like 
conditions, an adult mock circulatory flow loop was utilized. Investigators at the 
Cardiovascular Innovation Institute have developed the mock loop mainly for testing of 
cardiac devices in normal and pathologic states (7). Pantalos et al. describe the in vitro 
circulatory system, which can produce physiologically equivalent pressures, volumes, 
flows as to faithfully reproduce normal, heart failure, and partial cardiac recovery 
physiologic states as a platform for testing platform for testing cardiac devices (7).This 
mock loop circuit was used to complete in vitro dynamic flow testing on the cannula 
(Figure 24). 
 
FIGURE 24 - Adult circulation mock flow loop developed by Pantalos et al (7). 
Physiologically equivalent pressures, volumes, flows are used to reproduce normal, heart 
failure, and partial cardiac recovery physiologic states of the heart. 
57 
 
 The adult mock flow loop consists of a mock ventricle with atrial and apical 
inflow cannulation sites, mock systemic vasculature with aortic root and descending 
thoracic aorta outflow cannulation sites, and mock coronary vasculature. The mock 
ventricle is powered and controlled by a pneumatic driver. Figure 25 gives a diagram of 
the mock loop. This mock loop is able to faithfully produce the Frank–Starling response 
with physiologic characteristic hemodynamic parameters and pressure–volume 
relationships under a variety of testing conditions. The cardiac and vascular 
hemodynamic waveforms of the mock circulation are comparable to natural physiology 
in both magnitudes and morphologic features. 
 
FIGURE 25 – Diagram of the adult circulation mock flow loop developed by 
Pantalos et al (7). Due to its versatility and robustness, the mock loop is able to test the 
AVB system providing a powerful in vitro testing environment. 
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The versatility of this system allowed the entire aortic valve bypass system to be 
tested. The cannula was introduced to the apical cannulation site of the mock ventricle 
and was connected to a conduit and valve eventually connecting to a T-junction in the 
mock descending aorta. This setup allows for in vitro testing of the AVB system as a 
whole and provides conditions very similar to what the cannula would experience 
clinically. Using the pressure and flow instrumentation previously described, the mock 
loop was instrumented to measure: Aortic Flow (AoF), Aortic Pressure (AoP), Left 
Ventricular Pressure (LVP), Left Atrial Pressure (LAP), Flow though the AVB conduit 
(GRF), and Pressure inside the AVB conduit (GRP). 
 Choice of fluid was also important in creating near physiologic testing conditions. 
Glycerol was used as a blood analog in the flow loop. The viscosity of the glycerol used 
in the loop was 3.7 centipoise, which is very similar to blood. Investigators have shown 
that this material provides a good blood analog fluid for flow conditions characteristic of 
large arteries. Because the fluid is transparent and made from readily available and fairly 
inexpensive materials, it may be generally useful for in vitro hemodynamic studies, 
particularly those employing optical techniques (33). 
 
Computer Software Package 
A host of computer software programs were used in the design and analysis of the 
cannula. AutoCAD (AutoCAD 2008, San Rafael, CA) was used to create the initial 
model while SolidWorks (SP3.0 2009, Dassault Systems) was used to create the final 
cannula and AVB system model.  The schematics and CAD data files were sent to ATS 
Medical for fabrication. Primary analysis of data collected from mock loop experiments 
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and CFD computations was completed using the MATLAB (MathWorks, Inc., Natick, 
MA) software package.  
Characterizing hemodynamic parameter values were calculated using the custom 
MATLAB program HEART (Hemodynamic Evaluation and Assessment Research Tool) 
developed by Schroeder et al. (34). All hemodynamic parameters were calculated on a 
beat to beat basis and averaged over the entire data set to obtain a mean value for each 
parameter.  Sample hemodynamic waveforms for each data epoch and test condition were 
plotted for post-analysis to validate waveform fidelity. Microsoft Office 2007 software 
package (Excel, Word, PowerPoint) was also used for preparation of graphs and tables. 
Computation flow analysis was completed with the ANSYS CFD (ANSYS Inc., 
Canonsburg, PA, U.S.A.) software package. The CAD files of the cannula designs were 
loaded into ANSYS workbench project and the 3D models were checked for continuity. 
The model was then meshed using the AutoMesh function with the appropriate settings 
for fluid flow. Pre-solver software was used to define boundary regions and initial 
conditions. The CFX solver was then utilized and the computation ran until the solving 
equations converged upon a final solution. Post-solver component was then used to 
analyze and visualize the results. Stream lines, gradient profiles, vector fields, and slice 
planes were used for visual analysis while average, peak, and minimum values for 
various parameters such as flow rate, pressure, shear rate, and velocity at the boundary 
regions were calculated. 
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VII. RESULTS 
 
Static Flow Loop 
 The data was then plotted with the pressure drop vs. flow rate to determine the 
flow characteristics. As discussed previously, the resistance of the cannula can be 
measured by taking the change in pressure and dividing by the flow rate.  
R = ΔP / Q 
The steeper the slope of the pressure drop versus flow rate curve, the higher the overall 
resistance is to flow. Figure 26 shows the flow profiles for all cannula tested. The 
resistance decreases significantly as the size of the outer diameter is increased. 
 
FIGURE 26 – Flow profiles for all seven cannula tested in the static flow loop and shows 
resistance to flow decreases with increasing diameter size. Legend Key: C - cage, O – 
open, D – dome. Outer French (Fr) diameter sizes are given. 
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 Resistance values and the R-Squared value for each cannula are reported in Table 
X. The 28Fr (9.3mm diameter) cannulas had the highest resistance values among all the 
cannula. The 30Fr cannula had almost half the resistance of the 28Fr cannulas and 
resistance decreases slightly as size is increased from this size. The R-squared values are 
high with all cannula greater than 0.979 showing good linear approximation fit.  
 
TABLE X 
STATIC LOOP RESULTS FOR TESTED CANNULAS  
 
Legend: C - cage, O – open, D – dome. 
Outer French (Fr) diameter sizes are given. 
Units of Resistance = (mmHg*min)/L 
 
Blood Trauma  
Table XI presents the results from the blood chemistry and plasma free 
hemoglobin testing. Over the course of the 6 hour study all the blood chemistry stayed 
within normal values for the bovine model. The WBC, RBC, HGB, HCT, and PLT 
counts all decreased slightly while the plasma free hemoglobin slightly increases over the 
study period though this can be expected as the blood outside the body degrades over 
time. 
Resistance           
(linear regression 
model)
R-Squared
28-C 20.9 0.984
28-O 21.9 0.982
30-D 13.3 0.981
30-O 10.4 0.982
32-C 13.1 0.979
34-D 9.4 0.979
36-C 7.3 0.979
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All plasma free hemoglobin measurements were well under 100 mg/dL indicating 
little to no hemolysis. The device, the HemoCue Plasma/Low Hb, used to measure the 
plasma free hemoglobin has a linear measuring range between 0.3-30.0 g/L. The device 
manufacturer advises caution for evaluating instrument readings below 30mg/dL. 
 
TABLE XI 
RESULTS FROM TRAUMA MOCK LOOP TESTING 
 
 
The pfHb increased over the experiment to a final reading of 40mg/dL, which is 
slightly larger than the minimal detection levels of the HemoCue again showing no 
significant levels of hemolysis. 
 
Dynamic Flow Loop  
The flow rates for each cannula are presented in Table XII. For severe AS, the 
peak flow rate through the preliminary prototype was 0.6L/min, while the 32Fr and 36Fr 
provided flow rates of 1.65L/min and 2.55L/min, respectively. With the aortic root fully 
clamped off, the maximum flow rates through the prototype cannula was 1.49 L/min, 
while the 32Fr and 36Fr had flow rates of 3.31 L/min and 3.87 L/min, respectively.  
 
 
Blood wt. Flow Pressure Drop ACT WBC RBC HGB HCT PLT pfHb
g lpm mmHg sec thous/uL mill/uL % % thous/ul mg/dL
1030 Baseline 651 2.4 40 >300 5.34 6.8 8.6 22.7 889 10
1200 Sample -10 2.4 40 >300 5.46 6.77 8.6 22.5 877 20
1330 Sample -10 2.4 42 >300 5.39 6.77 8.6 22.5 863 20
1500 Sample -10 2.4 41 >300 5.3 6.77 8.6 22.5 851 30
1625 Sample -10 2.4 40 >300 4.93 6.72 8.6 22.4 846 35
1635 Sample -5 2.4 40 >300 4.9 6.7 8.6 22.4 824 40
Time Condition
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TABLE XII 
PEAK FLOW RATES FOR CANNULA UNDER DYNAMIC TESTING CONDITIONS 
 
 
The AVB system showed a trend of decreased transvalvular pressure difference 
for all three cannula under most conditions. Figure 27 shows the baseline valve gradient 
with the AVB arm clamped off and the valve gradient when the AVB system is in use.  
The largest difference can be seen for the severe arotic stenosis condition although the 
preliminary prototype showed no improvement. 
 
Aortic Stenosis Prototype 32Fr 36FR
None 0.34 0.85 1.17
Mild 0.40 - 1.15
Moderate 0.57 1.4 1.7
Severe 0.6 1.65 2.55
Complete 1.49 3.31 3.87
Flow (L/min)
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FIGURE 27 – Difference in valve gradient (LVP – AoP) from the adult 
circulation mock flow loop between baseline and with the AVB system. Improvement 
can be seen as the cannula diameter increases. The largest improvement can be seen in 
the 36Fr cannula for the severe aortic stenosis condition. 
 
Figure 28 shows the % conduit flow increases with cannula size. The prototype 
again showed poor performance, as only 15% of the fluid flow was through the cannula. 
The 32Fr cannula showed an improvement to 36%, while the 36Fr cannula had the best 
performance at 59%. 
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FIGURE 28 – Relative conduit flow as a percentage of total cardiac output. % 
Conduit flow provides a measure of the effectiveness of the cannula in the AVB system. 
The percentage increased as cannula size was increased. 
 
 
Computational Dynamic Flow Analysis 
 Two studies were performed on a 12mm diameter (36Fr) cannula to see the effect 
of number and size of the sideholes on wall shear stress, shear strain rate, and flow 
characteristics. For each computational run, a custom report was used to gather the flow 
parameters and create figures. A sample report is presented in Appendix IV. 
 
Number of Sideholes Study 
 The flow rates at the outlet for each cannula are presented in Figure 29. Flow 
slightly increased as the number of sideholes increased, although, the cannula with no 
sideholes had the highest flow of 4.1 L/min. These values remain very similar to one 
another with the largest difference being 0.3 L/min. 
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FIGURE 29 – Flow rates for 12mm diameter (36Fr) cannula with different numbers of 
sideholes. 
 
 Figure 30 presents a cross sectional view of the velocity profiles for all four cases. 
The largest velocities are seen in the cannula with no sideholes. In the cannulas with 
sideholes, the max velocities occur at the bottom of the most distal sideholes. These high 
velocity areas are the same areas that contained the largest shear stress, seen in Figure 31. 
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FIGURE 30 – Velocity profiles for the number of sideholes study. Four (Top Left), Eight 
(Top Right), Twelve (Bottom Left), and No Sideholes (Bottom Right).  
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FIGURE 31 – Shear wall stresses for the number of sideholes study. Four (Top Left), 
Eight (Top Right), Twelve (Bottom Left), and No Sideholes (Bottom Right). The highest 
wall shear rates are seen on the bottom edges of the most distal sideholes.  
 
 Flow rate and Reynolds numbers at the outlet as well as shear wall stress and 
strain rate are reported in Table XIII. The reported Reynolds numbers for all cases were 
greater than 3000 indicating turbulent flow at the outlet. Shear strain rate decreased as 
sideholes are increased. Flow and maximum strain rate both increase with addition of 
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sideholes though the No sideholes cannula has the largest values. Maximum shear 
stresses increases with addition of sideholes. 
 
TABLE XIII 
RESULTS OF NUMBER OF SIDEHOLES STUDY 
  
    
Size of Sideholes Study 
 The flow rates at the outlet for each of the four cannulas are presented in Figure 
32. Flow rate increased as size increased. Similar to the other study, the largest 
differences in flow between the cannulas was only 0.3 L/min. The cannula with no fillet 
had slightly more flow than the medium sideholes but remained less than the large 
sideholes.  
 
None Four Eight Twelve
Flow (L/min) 4.1 3.8 3.9 4.0
Reynolds # 3349 3096 3174 3293
Wall Shear Stress (mmHg)
    Max Shear Stress 0.124 0.144 0.152 0.165
Shear Strain Rate (s^-1) 258.4 187.6 141.1 118.4
    Max Shear Rate 891 851 829 876
Number of Sideholes
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FIGURE 32 – Flow rates for cannula in the size of sideholes study. The cannula with no 
fillet has the highest flow rates.  
 
 The cross sectional velocity profiles are presented in Figure 33. Similar to the 
number of sideholes study, the highest velocities are seen on the bottom edges of the 
sideholes most distal from the tip. The cannula with small sideholes experienced the 
largest wall shear stresses, which decrease with increasing size shown in Figure 34. 
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 FIGURE 33 – Velocity profiles for the size of sideholes study. Small (Top Left), 
Medium (Top Right), Large (Bottom Left), No Fillet (Bottom Right).  
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FIGURE 34 – Shear wall stresses for the size of sidehole study. Small (Top Left), 
Medium (Top Right), Large (Bottom Left), No Fillet (Bottom Right) 
 
 The results of this experiment are presented in Table XIV. Similar to the number 
of sideholes study, all cases have turbulent flow. Flow rate, Reynolds number and 
maximum shear stress increased with increasing size. The No fillet cannula showed 
slightly higher flow, less shear stress and less strain rate than the medium cannula. 
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TABLE XIV 
RESULTS OF SIZE OF SIDEHOLES STUDY 
 
 
 
VIII. DISCUSSION 
 
Static Loop 
 The results from this experiment provide two insights. First that the resistance to 
flow decreases with increasing cannula diameter and second that an “open” tip design, 
which is a design that incorporates an orifice at the most distal tip featuring 8 sideholes 
arranged in 2 sets of 4 openings, seen in Figure 35, is preferred over other designs 
studied. The diameter plays a large role in the resistance while the tip design plays a 
much smaller but still important role. These results were used to aid the design 
characteristics chosen for the final AVB model. 
  
Small Medium Large No Fillet
Flow (L/min) 3.8 3.9 4.1 4.0
Reynolds # 3093 3174 3320 3227
Wall Shear Stress (mmHg)
    Max Shear Stress 0.1383 0.152 0.164 0.156
Shear Strain Rate (s^-1) 189.5 141.1 109.3 68.8
    Max Shear Rate 1020 829 712.3 651.4
Size of Sideholes
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FIGURE 35 – ‘Open’ tip design that includes an open orifice with 8 sideholes displayed 
the best flow characteristics from the three designs studied in static loop testing. 
  
 This data shows the significant differences between the different sized cannula. 
The resistance values for the 28Fr cannulas are as high as 21.9 while the 36Fr cannula 
remains in single digits at 7.3. The R-Square values that represent the linear 
approximation of the resistances are correlated well and show a good fit. It is evident 
from the data that there is a sharp difference between the 28F and 30Fr compared to the 
other increments. This suggests that the diameter plays a large role in the resistance and 
at a critical point between these two sizes. It may be undesirable to have an apical 
cannula this small due to the likely drop in flow rates. From this data it is favorable to 
select a cannula size of 30Fr (10mm) or larger. 
 To validate the data obtained, pressure drop vs. flow rate graphs were compared 
to ones obtained from the cannula manufacturer (35). The data obtained from the static 
loop testing closely matches the pressure/flow plots obtained from the manufacturer, an 
example can be seen in Figure 36. The figure shows that the flow rate and pressure drop 
values measured (Figure 36– right) are almost identical to the values obtained from the 
manufacturer (Figure 36– left). 
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FIGURE 36 – Pressure Drop vs. Flow Rate data obtained from the cannula manufacturer 
to the left with data obtained from static loop testing on the right. The top figure shows 
the ‘open’ tip Sarns Malleable Venous Return Catheters while the bottom shows the 
‘cage’ tip Sarns Venous Return Catheters. The data obtained from the manufacturer 
closely matched data obtained and validates observations made in the experiment. 
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This data from the manufacturer also shows the large differences seen as the 
diameter of the cannula is decreased. Specifically, this data also shows that the 28Fr and 
smaller cannula show a significantly increased resistance compared to larger cannula. 
Also the critical point where the resistance increases dramatically is in the area between 
28Fr and 32Fr for all three of the cannula designs. This confirms the observations that the 
diameter size plays the most important factor in resistance to flow and the design of the 
tip plays a secondary but important role. 
Comparing the plots between the three designs, the results show that the open tip 
design has lower flow resistance across almost all sizes. It can be inferred that the orifice 
at the tip with the addition of sideholes along the body are important features that 
contribute to improved flow characteristics.  
Explanation of these results can be found in comparison of the features of the 
three designs. The cage design is primarily a design where the tip allows flow through 
openings at the very distal end and features no sideholes along the body of the tip. The 
dome design, in contrast, has no opening at the distal most point and has all of the flow 
come through 8 sideholes along the body of the tip. It seems that the open design features 
both of these characteristics with an orifice at the distal tip and sideholes along the body 
and show superior flow characteristics compared to the dome and cage designs. 
 
Blood Trauma 
The results from this experiment indicate that there is minimal to no hemolysis 
caused by flow in the preliminary prototype. This study gives confidence for use of the 
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fabrication material (pyrolytic carbon) and the tip design of the cannula (one with an 
open orifice at the distal most tip with sideholes along the body of the tip).  
The results from this study show minimal to little hemolysis using the preliminary 
prototype cannula. The cannula has an outer diameter of 7mm at the distal-most tip and 
as such had a higher resistance to flow compared to the cannulas studied in all 
experiments performed. The values for all blood chemistry and plasma free hemoglobin 
showed little change from baseline to the study endpoint. The size and design of the 
cannula did not shear or damage the red blood cells in a significant manner.  
The biocompatibility of the pyrolytic carbon was shown to be a good choice as a 
fabrication material. The strong track record for use of this material in other medical 
devices, most notably mechanical valves, has been well documented and is discussed 
previously. The use of the anticoagulation drug, heparin, prevents an analysis on possible 
thrombus formation, though the use of CFD can pinpoint possible stagnation points. 
 
Dynamic Flow Loop 
The results from the adult mock circulation testing are similar to those obtained in 
the static loop testing. The results show that the preliminary prototype is too small to be 
clinically effective as a treatment for aortic stenosis. Flow rate and % Total flow through 
the conduit increased with increasing cannula size. The results show a trend of 
improvement in valve pressure difference between stenotic baseline conditions and the 
mock loop circuit with the AVB system. These results aid in development of a final 
design for the AVB system. 
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These results show that the size of the cannula play a critical role in improvement 
of aortic stenosis condition. This data also shows substantial improvement only when the 
aortic stenosis is severe. There is a significant difference between the prototype and 32Fr 
compared to the difference between the 32Fr and 36Fr. These results are similar to the 
static flow results where there exists a critcal point between 30Fr and 32Fr (10mm and 
10.7mm) in the tip size that critically impedes flow through the cannula. 
 When studying the % conduit flow, the 36Fr shows improved performance over 
the 32Fr and prototype. For comparison, a recent investigator presenting early and 
midterm hemodynamics after AVB surgery reported initial relative % conduit flow to be 
63%+- 10% for 47 patients who had received AVB surgery (29). These results show that 
the 36Fr cannula is the best choice for treatment of severe aortic stenosis of the three 
cannulas studied. The size of the 36Fr cannula (12mm) may be the smallest cannula tip 
size that will still give significant improvement in the valve gradient for patients with 
aortic stenosis. 
 
Computational Flow Dynamics Analysis 
 The two blood damage phenomena potentially occurring in an in implant of a 
blood contacting artificial material are thrombosis and hemolysis. Thrombosis refers to 
the formation and growth of blood clots. Hemolysis is hypothesized to be a function of 
cellular exposure to high shear stress and the length of time over which this exposure 
occurs. The processes that cause thrombosis and hemolysis to occur in complex flow 
situations are still not completely understood. The general understanding is that cellular 
exposure to high shear stresses can lead to hemolysis (36) and platelet activation (37) 
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while regions of low shear stress and/or flow stagnation can be susceptible to thrombus 
deposition (38). 
 Blood is a suspension consisting of primarily red blood cells, along with other 
formed elements which contribute to its viscoelastic behavior. Blood behaves as a 
Newtonian fluid at shear rates above 500 s-1. At shear rates lower than 50 s-1 the viscosity 
of blood increases exponentially, due to the formation of large aggregates of erythrocytes. 
The presence of shear and strain stresses are important for the ideal biocompatibility with 
the body. The best situation is to have shear stress throughout the flow just high enough 
to prevent aggregation and thrombus growth, but not so high as to cause trauma or 
platelet activation.  
 Previous studies done by investigators have found that shear stresses on the order 
of 1500-4000 dynes/cm2 can cause hemolysis (39). Sub-lethal damage to red blood cells 
can occur at turbulent shear stresses of 500 dynes/cm2 (40). Platelets are more sensitive 
and can be damaged by shear stresses ranging from 100-500 dynes/cm2 though this is 
also very much dependent on the duration of the applied shear stress (41). The wall shear 
stress from the CFD analysis can provide a prediction for hemolysis and platelet 
activation. Comparisons between the cannulas can be made to evaluate design choices. 
   
Evaluation of Cannulas 
 The highest flow rates were seen in the No sideholes cannula and the Large 
sideholes cannula with both having 4.1 L/min flow. No sideholes cannula had a lower 
max shear stress (0.124 mmHg) than the Large cannula (0.164 mmHg). The Large 
cannula has larger areas of lower shear stresses located near the tip. Although it seems a 
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little counterintuitive, the cannula with no sideholes showed the best blood 
biocompatibility of all the cannulas studied. This does not make this cannula the ideal 
choice for this application though as the differences between the cannulas is still only 
slight and other factors such as device safety play a role in selection of the best cannula. 
 The more fully developed flow in the tube with no sideholes has walls that are 
washed and the shear stress is safely low giving it better blood compatibility the other 
cannulas studied. The sideholes, on the other hand, produce high shear stresses at the 
distal end of their openings, and could cause recirculation regions downstream of the 
holes that promote thrombus growth and attachment. The increase in number of sideholes 
in essence makes the tube shorter, since a majority of the flow is coming in through the 
distal holes and very little is coming through the proximal holes. 
 The shape of the ventricle around the cannula once inserted likely has a great 
amount of influence on the direction of flow. The surgical placement of the cannula is 
paramount to the performance of the cannula. If the cannula was improperly placed with 
one side of the tip lying against a ventricular wall, then full flow will not be achieved. In 
terms of safety, the addition of sideholes allows fluid to enter from all directions so flow 
rates can be more consistent while the ventricle is pumping. As the No sidehole cannula 
has only one inlet, if something were to occur to block or partially occlude the opening 
(i.e. cannula is against the ventricular wall) the flow could diminish in the conduit and 
may allow stagnation of blood in the entire AVB system. 
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Wall Shear Stress 
 When looking at the wall shear stress, the average may not be a very useful 
indicator and can be very misleading.. There is so much surface area at the proximal part 
of the tube that has very low wall shear stress that when added to the higher shear stresses 
at the distal sideholes, the average shear stresses become diluted. Instead investigation of 
max shear stress may be more helpful and the areas that they occur. 
  
FIGURE 37 – Wall shear stress for all cannulas studies. Color above blue represents a 
shear stress level that exceeds 0.125 mmHg (166 dynes/cm2). The addition and size of 
sideholes increases the areas of high shear stress.  
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 To directly compare the wall shear stresses and determine the areas of high shear 
stress, the scales on the figures were adjusted to highlight areas higher than this threshold. 
Figure 37 shows all cannulas studied, the blue area represents any area under a minimum 
threshold of 0.124 mmHg (166 dynes/cm2), while any color above it represents areas of 
higher stresses. As the number and size of the sideholes increases, the areas of higher 
stress increase. The maximum shear stress measured was 0.165 mmHg (220 dynes/cm2), 
which is still significantly lower than the threshold for hemolysis of 1500 dynes/cm2. 
 The levels of shear stress seen in all the cannulas are lower than the critical 
amount needed to activate platelets. At 150 dynes/cm2, it takes 300 s for platelet 
aggregation to occur (41). The CFD flows are assumed to be during systole, so there is 
not enough duration of shear stress to cause activation at the calculated values levels. 
Even though there are differences between each design, the levels of wall shear stress 
remain with-in safe values for hemolysis and platelet activation for all cannula.  
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FIGURE 38 – Wall shear stress for all cannulas studies. Any color below red represents a 
shear stress level lower than 0.02 mmHg (27 dynes/cm2). The addition and size of 
sideholes increases the areas of low shear stress near the tip and proximal sideholes.  
  
 In a similar way, the areas of low shear stress were also compared for the 
cannulas studied. Figure 38 shows areas of lower shear stress for colors below the red 
threshold of 0.02 mmHg. This figure highlights the increase of lower shear stress areas as 
the number and size of the sideholes is increased. As more flow enters the more distal 
84 
 
sideholes, the proximal sideholes have less shear energy imparted on the wall surface. 
 These areas could potentially lead to thrombus formation. The fluctuations 
between systole and diastole may help prevent thrombus formation. Looking at the 
velocity plots, examining the streamlines (Figure 39), and pressure field plots show flow 
through the proximal holes.  
 
FIGURE 39 – Streamlines for 12 holes cannula 
 
 Likely just as important for this analysis is in the choice of the material used in 
fabrication. The nature of thrombus and platelet attachment is still an area of broad 
research.  In vitro or animal in vivo studies are needed to properly study the effects of 
thrombus formation for the cannulas. The use of pyrolytic carbon and the application of 
the Forcefield technology described previously could greatly increase the 
biocompatibility of the cannula. 
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Effect of No Fillet 
 The fillet used on all the cannulas are part of the fabrication process that smooth’s 
out the rough edges created during fabrication. Sharp edges on the cannula can possibly 
damage tissue when implanted. These edges are also rounded, as it is believed that the 
rounded edges can help direct stream lines of flow into the cannula and reduce the 
concentration of high wall shear stress at the distal edges of the sideholes. Figure 40 
shows a cross sectional velocity vector field for the medium and no fillet cannulas. 
 
FIGURE 40 – Velocity vector fields on cross section of Medium and No Fillet cannulas. 
The No Fillet Cannula had slightly higher flow and similar shear stress properties to the 
Medium cannula. 
 
 It can be seen in Figure 40 that the flow is indeed directed and shows a more 
uniform vector profile than what is seen in the no fillet cannula. The two cannulas are 
identical in size and geometry except for the addition of the fillet. Interestingly, the flow 
rate and Reynolds number are slightly higher in the no fillet cannula. Maximum shear 
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stress and the distribution of high/low areas of stress do not show many differences, 
however higher resolution simulation of the flow over the distal edges of the sideholes 
may show the expected reduction in wall shear stress concentration produced by rounding 
these edges.  
 
Additional Benefits of AVB Technology 
 Another possible benefit of the AVB system may be a brain protective advantage 
over aortic valve repair. Balaras et al have completed a computational model that show 
that cerebal blood flow is increased to the aortic head vessels even with small conduits 
(10mm). This provides an advantage over typical aortic valve repair as there is a much 
higher risk for stroke during operation and postoperatively in AVR for the high risk 
patient groups. Figure 41 from their report shows the systolic flows for pre-operative, 
20mm conduit, and 10mm conduit. 
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FIGURE 41 – Results from Belaras et al. Through computational modeling a brain 
protective advantage is presented for AVB over AVR. They also conclude that cannula as 
small as 10mm can relieve left ventricular outflow tract obstruction in critical aortic valve 
stenosis (42). 
 
 The effect of AVB configuration may decrease the long-term risk of cerebral 
thromboembolism. The conduit provides a second path that possible clots or emboli can 
be shot into the peripheral vasculature instead of ending up in the cerebral vessels. They 
report that in all cases modeled, cerebral blood flow remained the same post-operatively 
from pre-operative levels (42). The brain was adequately supplied from blood ejected 
through the native aortic valve. The study also concluded that cannula as small as 10mm 
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in diameter can relieve left ventricular outflow tract obstruction in critical aortic valve 
stenosis. 
 
Type of Flow 
 The flow is split between the native stenotic valve and conduit in an interesting 
fashion. Surprisingly the pressure gradients are different for these two paths. The conduit 
is characterized by minimal directly measured pressure gradients. Clinically the low 
conduit gradient has been confirmed in patients while the pressure gradient for the native 
aortic valve remains higher averaging 17 mmHg (29). The difference between these 
gradients is almost 4-fold.  
 The difference implies that the energy loss experienced by the blood element 
moving through the stenotic valve is much higher than the one experienced by a blood 
element moving through the conduit. Losses in the conduit are primarily due to shear 
stresses from the conduit walls and losses from the prosthetic valve as well. In contrast, 
losses in the native aortic valve are through kinetic energy as blood decelerates 
inefficiently across the valve. These losses are higher than ones due to wall stress and can 
be amplified in the case of turbulent, disturbed flows (29). 
 The difference in mean gradients is consistent with the split of flow between the 
two elements. Data from the dynamic flow loop, clinical data, and computational data all 
show this spit of approximately 60:40 in relative % flow in the conduit and aortic valve 
respectively. The results suggest, as some researchers have described, that the flow split 
is determined largely by ventricular systolic geometries and to a small extent by the 
gradient across the native aortic valve (29). 
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Cannula Size 
 The largest question in the development of this technology is: what is the smallest 
size that can be used to achieve adequate relief? The benefits of decreasing the conduit 
sizes are many with the most important being a decrease the intraoperative risk in the 
surgical insertion of the conduit. A smaller cannula translates into a smaller stab incision, 
less bleeding in left ventricular apex, and less suturing needed to secure the cannula. The 
currently used systems commonly use conduits and components that are 20mm in 
diameter, though many believe that this size could be much smaller and still obtain 
adequate treatment of aortic stenosis. Brown and Gammie state, “Because the conduit is a 
second avenue for left ventricular outflow, we believe that a conduit smaller than what 
would normally be used for a conventional aortic valve replacement is acceptable and in 
most instances desirable” (23). 
 The tip size was chosen on basis of the experiments run and on clinical data. Most 
AVB apical cannulas in the past have been 20mm in diameter. As the technique gains 
more usage though, investigators are using smaller and smaller cannula for the procedure 
(3). Vliek et al. recently published clinical data on hemodynamics for a number of sizes 
of cannulas used that ranged from 20mm to 12mm. They found that cannula size did not 
significantly affect % flow in the conduit, but that there was a relationship between 
cannula size and valve pressure gradient (29). Figure 42 shows the data from this report, 
there is a upward trend in aortic valve gradient as the cannula size decreases (Figure, 
Top) while there is no effect on % flow due to cannula size (Figure, Bottom). 
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FIGURE 42 – Data from Vliek et al. showing upward trend in valve gradient as the 
cannula size decreases (Top) while there is no effect on % flow due to cannula size 
(Bottom) (29). 
 
 The mock loop studies that were performed in this thesis work, specifically the 
results from the preliminary prototype, show that cannula beneath 10mm are not suited 
for use in AVB. Belarus et al. presented a computational model where 10mm cannula can 
effectively treat aortic stenosis though more favorable flow was seen in larger cannula, 
such as those presented in the mock flow loop experiments in this thesis work (42). 
Clinical data shows favorable results for cannula that are 12mm in diameter (the smallest 
conduits in current use).  
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Tip and Sideholes 
 The design of the tip was based from the results seen from the static loop testing. 
The open straight tip will allow for a larger amount of inflow than a tip that narrows to a 
smaller opening diameter. The mock loop flow tests show that a design that incorporates 
an open orifice at the distal most tip and inclusion of sideholes along the body is the most 
desired design. The use of sideholes is to decrease sidewall shear stress and maximum 
blood velocities to avoid hemolysis. Park et al. used a computational model to study the 
effect of sideholes in venous cannula. They found that flow rates in the cannula are not 
proportional to the number or arrangement of sideholes. They concluded though that 
larger number of sideholes can reduce the mean shear rate (43).  
 
  
IX. CONCLUSIONS 
  
Static Loop Testing 
In this study, a simple test to look at the most important features in the cannula tip 
was completed. Three different designs were investigated, which showed that diameter 
plays a large role in the resistance while the tip design plays a much smaller but still 
important role.  The key findings were: (1) the resistance to flow decreases with 
increasing cannula diameter and (2) an “open” tip design, which is a design that 
incorporates an orifice at the most distal tip featuring 8 sideholes arranged in 2 sets of 4 
openings, is preferred over other designs studied. Also, it demonstrated that diameter 
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sizes above 10mm (30Fr) are favored, since smaller cannulas have a much higher 
resistance. 
 
Limitations 
A relatively small sample size (n=7) and evaluation of only three clinically used 
designs were included in the experimental design to demonstrate feasibility of concept. 
These designs were selected to highlight important characteristics of the tip design and to 
simplify the analysis of these cannula. Knowledge of the manufacturer’s experimental 
methods is incomplete (proprietary intellectual property), making comparision of 
experimental data a challenge, though the density and viscosity of the Plasma-Lyte 
solution used in the current experiment is nearly identical to the water that the 
manufacturers used for their in vitro evaluations and should have the same flow 
characteristics. Some of the cannulas used for study were expired for medical use, though 
the flow characteristics of the cannula should be unaffected, since the expiration date 
relates more to the sterility of the cannula than degradation of the materials. 
 
Blood Trauma Testing 
 No hemolysis, platlet activation, or blood damage observed with the prototype 
cannula over 6-hour test period in mock flow loop primed with bovine blood.  Complete 
blood chemistry and plasma free hemoglobin did not vary significantly from baseline 
values over the entire test period. The prototype was fabricated from PYC and has ‘open’ 
tip profile, the same design that was favored by the static loop tests. This prototype also 
had the smallest diameter (7mm) of any cannula tested in all experiments therefore 
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subjecting the blood to the highest resistance of any of the designs. Even under these 
conditions the prototype showed excellent biocompatibility. This biocompatility could 
also be amplified if incorporated with the Forcefield surface alteration in future studies. 
 
Limitations 
The main limitation for this study that arise are unrelated to the device or 
experimental procedure, and mainly lie in the variability of the blood samples. Due to the 
inherent variability in blood sources, performance of in vitro studies and subsequent 
analysis and comparison of results can be problematic. For example, different species 
blood (human vs. animals) used for testing thrombogenicity show differences in 
mechanical fragility and rheological behavior (44). 
The use of the HeartMate II VAD device requires anticoagulation, in this case 
heparin, to prevent possible clotting and thrombus growth inside the pump. Typical 
clinical application of the cannula in AVB does not use anticoagulation  therapy 
following implantation. The HeartMate II was also only run at one fixed pump speed 
setting (8400rpm), creating a static flow for the duration of the experiment so the effects 
of blood being subjected to more physiological-like conditions was not possible. More 
accurate testing environment would include dynamic pressure and flow changes, 
representing the systolic and diastolic pressures.  
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FIGURE 43 – Cross sectional view of the HeartMate II. Blood in the experiment 
were in contact with the small clearances inside the pump and may affect the results of 
the trauma study. 
 
The HeartMate II has small clearances and two rotor bearings that contact the 
blood; Figure 43 shows a cross sectional view of the device. Some results from this 
study, specifically the changes in the bloodwork and plasma free hemoglobin, may have 
been the product of the HeartMate II rather than the implementation of the cannula. 
Clinical investigations have reported minimal (< 30 mg/dl) hemolysis using these 
devices, though continued investigation of blood trauma associated with rotary pumps is 
ongoing.  
 
Dynamic Loop Testing 
The three cannulas tested in the adult circulation mock flow loop have provided a 
key insight to the minimal cannula diameter size, 12mm, which will have a clinical 
impact in treating aortic stenosis. The 36Fr cannula (12mm diameter) shows much better 
performance than the two smaller cannulas tested. The study also has shown the 
performance of the preliminary prototype (7mm diameter) is too poor for clinical usage 
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in the AVB system. The relative % conduit flow of the 36Fr cannula, 59%, is comparable 
to those in current clinical use for AVB and shows an improvement of 30mmHg in the 
valve gradient for the severe AS case. 
 
Limitations 
To minimize measurement errors, post-calibrations were recorded for all pressure 
and flow measurements to obtain linear gain and offset calibration factors. The flow loop 
also used mechanical valves for the mitral, aortic, and the 19mm valve used in the AVB 
system. These valves create a ‘ringing’ effect that can be seen in the waveforms, this can 
be especially seen in the AoP signal in the sample plots in Appendix II. This effect 
distorts part of the pressure waveform immediately following the closing of the valve. 
Comparing data using these valves to in vivo data could be flawed. Though data is 
averaged and peak beat-to-beat waveform data is inspected for each file, minimizing the 
possible error.  Despite the limitations, this study provides vital information on the effect 
of cannula size on flow performance.  
 
Continuous Flow Dynamics Testing 
 The analysis concluded that flow rate and wall shear stress increase with the 
addition of sideholes. Increasing the size of the sideholes decreases the shear stresses and 
increases flow. All wall shear stresses were significantly lower (maximum value from all 
designs was 220 dynes/cm2) than the threshold for hemolysis (1500 dynes/cm2) and 
platelet activation levels. Flow was shown to be turbulent for all cannulas tested with 
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Reynolds values being slightly greater than 3,000. The highest flow conditions were seen 
with the cannula with no sideholes and the cannula with large sideholes.  
 The cannula without sideholes showed the best blood biocompatibility in terms of 
ideal wall stress magnitude and area. Due to safety issues, sideholes are an important 
addition to the design. Increasing the number of sideholes may increase flow, but my also 
lead to areas of low shear stress near the tip, which may lead to thrombus formation. In 
vitro  and/or in vivo studies are needed to further investigate these effects. 
  
Limitations 
The steady flows used in both studies do not represent the average flow rate 
through the cannula and only represent the flow rate during systole. Physiologic pulsatile 
flow may affect the velocity profiles and, therefore, the comparisons among cannula. The 
pressure boundary assumption was based upon a clinical median value, which averaged 
from 3 different sizes of cannula and represents the entire conduit as opposed to just the 
cannula. A different boundary pressure may be more accurate than the 6 mmHg used in 
these simulations. The prosthetic valve in the conduit may create more resistance than the 
cannula and it is uncertain what the true pressure difference is for the cannula only.  
 This computational flow analysis also does not account for the left ventricular 
geometries that may play a role in flow characteristics. There are two paths for blood to 
take in this system, the aortic valve and the AVB conduit, and the shape of the ventricle 
may have a role in the split of flow through each. 
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Summary of Experimental Results 
 The cannula studies performed have aided in the development of the 
specifications for a design of an apical cannula. In early investigations, the prototype 
design was fabricated as a potential AVB therapy. Results from the static loop testing and 
specifically the dynamic loop testing proved this design to be a poor choice for 
application in AVB system. However, the insights learned from these studies have 
contributed to a design of a new apical cannula presented in the next in Section X. Table 
XV provides a summary of the results from experiments performed. 
 
TABLE XV 
SUMMARY OF RESULTS FROM EXPERIMENTAL STUDIES 
 
 
Test
Resistance to flow decreases with increasing cannula diameter
Design that features an open distal oriface and sideholes along the 
tip of the body favored over three designs tested
Preliminary Prototype fabrication material shows good 
biocompatibility
No significant hemolysis or blood damage due to cannula 
Preliminary Prototype developed not large enough for clinical 
improvement of AVB
Flow rate and % conduit flow increases with cannula diameter size
12mm diameter tip (36Fr) smallest cannula whose % conduit flow 
matches clinical data for currently used AVB systems
Flow rate and shear stresses influenced by number and size of 
sideholes
Wall shear stress below threshold for hemolysis damage and 
platelet activation for all designs
Static Flow Loop 
Blood Trauma
Dynamic Flow Loop
Result
CFD Analysis
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These experiments have given insight for specifications of a cannula design specifically 
for three main design points: 1) Cannula Size, 2) Biocompatibility, 3) Tip Characteristics.  
 
1. Cannula Size – The dynamic loop testing showed that the preliminary prototype 
was not large enough to be an effective treatment for AVB. The dynamic and 
static loop testing both showed a critical point in flow characteristics between 
10mm and 10.7mm (30Fr and 32Fr) where the resistance increases dramatically. 
This is also supported by the cannula manufacturer pressure vs. flow rate data. 
Data from both experiments suggest using cannula 10.7mm in outer diameter or 
larger.  
 
2. Biocompatibility – The preliminary prototype showed good biocompatibility for 
use of pyrolytic carbon as a fabrication material. Both the blood trauma mock 
loop and CFD analysis show no hemolysis and minimal to no platelet activation. 
Future application of the Forcefield technology will also greatly increase the 
biocompatibility of the cannula. 
 
3. Tip Characteristics – Static flow loop showed a design that incorporated an open 
orifice at the distal tip with sideholes was favored over other designs studied. The 
CFD analysis show flow rate increased with addition of sideholes while 
increasing the size of the sideholes decreased the shear stresses. Turbulent flow 
was also seen to dominate the flow during systole in all simulations. 
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X.  FINAL APICAL CANNULA DESIGN 
 
 The results of the experiments have led to the final proposed design for an apical 
cannula. The cannula and model for the AVB system are now presented. 
 
 Apical Cannula Design 
 The final design for the apical cannula was developed from the results of 
experiments performed in this thesis work. The cannula consists of a 12mm (36French) 
outer diameter opening with an open tip design shown in Figure 44.  
 
Figure 44 – Apical cannula design developed from mock loop studies created with CAD 
software (SolidWorks SP3.0, Dassault Systèmes). The selected criterion includes a 12mm 
(36Fr) outer diameter, an open tip design, and is fabricated from pyrolytic carbon. All 
units are in millimeters. Upper Left - Sectioned Side view, Lower Left – Top view, 
Lower Right – Right Sided view, Upper Right – 3D rendered drawings. 
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 The tip of the cannula is 12mm in diameter, which adapts to a larger 17mm at the 
base of the cannula where it attaches to the conduit material. There is a small 0.5mm 
engraved ring at the base of the 17mm section of the cannula so that graft material may 
be sewn onto the cannula. The light 0.1mm etchings are cosmetic and intended to assist 
the surgeon with implantation. In a blood-soaked operation field, the etchings give a 
tactile feel to the cannula and can aide in implantation so the surgeon can know how far 
the cannula is inside the apex of the left ventricle.  
 The tip characteristics have a straight, open orifice at the proximal tip with eight 
sideholes arranged offset in two rows. These openings also feature rounded edges and are 
smooth to improve biocompatibility and flow characteristics. The size and number of 
sideholes on the cannula are the same as medium, eight sideholes model studied in the 
CFD analysis. The proposed cannula is the same cannula model used in the CFD studies. 
Appendix IV gives the results report of CFD analysis of this model.  
 The fabrication of the apical cannula will be identical to that used on the 
preliminary prototype. The thickness of the pyrolytic carbon is based from proprietary 
fabrication methods. The cannulas studied in static and dynamic mock flow loops all had 
wall thicknesses slightly larger than 1mm. The proposed apical cannula has a wall 
thickness of 1.3mm. 
  
Aortic Valve Bypass System 
The proposed AVB system consists of the apical cannula connected to a right 
angle bend adapter, graft material, and mechanical valve shown in Figure 45. The apical 
cannula has a 12mm tip (36Fr) that widens to 17mm at the base. The cannula connects to 
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17mm Dacron graft material wire reinforced to conform to a right angle bend. This 
conduit has a 17mm pyrolytic mechanical valve. The conduit is 80mm in length, which is 
the best approximation for the distance between the left ventricular apex to the 
descending aorta in an average patient. 
 
 
FIGURE 45 – Proposed design for the AVB system. The apical cannula adapts 
into a right bend adaptor and into a size 17mm Dacron graph. The valve intended for use 
is a mechanical valve also sized to 17mm. This model was designed through use of CAD 
software (SolidWorks SP3.0, Dassault Systèmes) and used in CFD analysis. 
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Closing Comments 
 This thesis has presented the possible advantages that aortic valve bypass has over 
aortic valve repair in high risk patient groups. The experiments performed have been used 
to develop a new design for the apical cannula component in the aortic valve bypass 
system. This incorporates new technologies, techniques, and fabrication materials. The 
‘forcefield’ technology and Seldinger insertion technique are exciting prospects to make 
this design feasible for market development. 
 Aortic valve bypass results in a low gradient across the native stenotic valve and a 
small gradient across the conduit. The results from the mock loop experiments, CFD 
analysis, clinical data, and findings from other researchers have aided in the creation of a 
new apical cannula. It is hoped that this design will be a more favorable design over 
currently used apical connectors. Further studies are needed to validate this design. 
 
Future Work 
 Future work on this system would include experimental analysis on the proposed 
cannula. It will need to be fabricated and tested against currently available cannula and 
apical connectors using methods similar to this thesis work. In vivo animal model studies 
would aide in biocompatible and ultimate efficacy of the AVB system. In addition, future 
studies may further investigate the shape of the sideholes. For this study only oval shaped 
sideholes with 0.5mm fillet were studied. There may be alternate geometries that could 
improve flow characteristics. 
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1. File Report 
Table 1.  File Information for CFX 
Case CFX 
File 
Path 
C:\Users\Joel\Desktop\36Fr_straight_tip_17mm_4Hole_new_files\dp0\CFX\CFX\CFX_
037.res 
File 
Date 
02 December 2010 
File 
Time 05:58:51 PM 
File CFX5 
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Type 
File 
Versio
n 
12.0 
  
2. Mesh Report 
Table 2.  Mesh Information for CFX 
Domain Nodes Elements 
Default Domain 149169 814855 
  
3. Physics Report 
Table 3.  Domain Physics for CFX 
Domain - Default Domain 
Type Fluid 
Location B1117 
Materials 
Blood 
     Fluid Definition Material Library 
     Morphology Continuous Fluid 
Settings 
Buoyancy Model Non Buoyant 
Domain Motion Stationary 
Reference Pressure 1.0000e+00 [atm] 
Turbulence Model k epsilon 
Turbulent Wall Functions Scalable 
  
Table 4.  Boundary Physics for CFX 
Domain Boundaries 
Default 
Domain 
Boundary - Inlet 1 
Type INLET 
Location F1118.1117, F1132.1117, F1133.1117 
Settings 
Flow 
Direction Zero Gradient 
Flow Regime Subsonic 
Mass And 
Momentum 
Static Pressure 
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     Relative 
Pressure 5.0000e+01 [mm Hg] 
Turbulence Medium Intensity and Eddy Viscosity Ratio 
Boundary - Outlet 
Type OUTLET 
Location F1177.1117 
Settings 
Flow Regime Subsonic 
Mass And 
Momentum 
Static Pressure 
     Relative 
Pressure 4.4000e+01 [mm Hg] 
Boundary - Default Domain Default 
Type WALL 
Location 
F1119.1117, F1120.1117, F1121.1117, F1122.1117, F1123.1117, 
F1124.1117, F1125.1117, F1126.1117, F1127.1117, F1128.1117, 
F1129.1117, F1130.1117, F1131.1117, F1134.1117, F1135.1117, 
F1136.1117, F1137.1117, F1138.1117, F1139.1117, F1140.1117, 
F1141.1117, F1142.1117, F1143.1117, F1144.1117, F1145.1117, 
F1146.1117, F1147.1117, F1148.1117, F1149.1117, F1150.1117, 
F1151.1117, F1152.1117, F1153.1117, F1154.1117, F1155.1117, 
F1156.1117, F1157.1117, F1158.1117, F1159.1117, F1160.1117, 
F1161.1117, F1162.1117, F1163.1117, F1164.1117, F1165.1117, 
F1166.1117, F1167.1117, F1168.1117, F1169.1117, F1170.1117, 
F1171.1117, F1172.1117, F1173.1117, F1174.1117, F1175.1117, 
F1176.1117, F1178.1117 
Settings 
Mass And 
Momentum No Slip Wall 
Wall 
Roughness Smooth Wall 
  
4. Solution Report 
Table 5.  Boundary Flows for CFX 
Location Type Mass Flow 
Momentum 
X Y Z 
Default Domain Default Boundary 0.0000e+00 2.0251e-05 -2.5772e-01 8.6553e-05 
Inlet 1 Boundary 3.9935e-02 1.4347e-04 -7.2421e-01 2.9014e-04 
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Outlet Boundary -7.0625e-02 -2.8056e-06 9.7880e-01 -1.7091e-06 
  
Table 6.   
  Average Velocity Max Velocity Min Velocity 
Inlet 1.868e-02 [m s^-1] 4.994e-02 [m s^-1] 4.261e-03 [m s^-1] 
Outlet 3.912e-01 [m s^-1] 4.502e-01 [m s^-1] 3.589e-01 [m s^-1] 
        
  Flow Flow [liter^1 min^-1]   
Inlet 1.123e-04 [m^3 s^-1] 6.741e+00   
Outlet 6.344e-05 [m^3 s^-1] 3.806e+00   
        
        
        
  Reynolds Number     
Outlet 3.096e+03     
  
Figure 1. 
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Figure 2. 
 
Figure 3. 
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Figure 4. 
 
Figure 5.  Inside wall shear stress 
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Figure 6.  Outside wall shear stress 
 
Figure 7. 
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Figure 8. 
 
Figure 9. 
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Figure 10. 
 
5. User Data 
Table 7.   
Wall Shear Stress Average Max Min 
Default Domain Default 2.973e-02 [mm Hg] 1.444e-01 [mm Hg] 1.175e-05 [mm Hg] 
        
Shear Strain Rate Average Max Min 
Default Domain Default 1.876e+02 [s^-1] 8.514e+02 [s^-1] 1.594e+00 [s^-1] 
        
Volume       
Default Domain 3.668e-05 [m^3]     
        
Area       
Inlet 1 6.015e-03 [m^2]     
Outlet 1.622e-04 [m^2]     
Default Domain Default 3.212e-03 [m^2]     
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